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INTRODUCTION 
The faecal flora of patients with Crohn's disease of the ileum has been 
found to differ from that of healthy subjects (Wensinck, 1975; 1976). 
Patients with Grahn's disease have a higher number of anaerobic gram-
negative bacteria and about 10% of the flora are anaerobic, gram-posit-
ive coccoid rods that are not usually found in the faeces of healthy 
subjects. Wensinck found no evidence that the flora abnormality was in-
fluenced by the duration of the inflammation or by ileocaecal resection. 
Serum agglutinins were found in a considerable percentage of patients 
with Crohn•s disease, directed against some strains of the coccoid rods, 
later identified as Eubacterium and Peptostreptococc~s species. In pat-
ients suffering from other diseases and in healthy subjects, antibodies 
were found less frequently. The interpretation of these findings is the 
subject of this thesis in which particular attention is paid to the sig-
nificance of the agglutinins in Crohn•s disease and the use of the ag-
glutination reactions as a diagnostic test. 
In Chapter 2 recent studies on microbial agents in tissues of patients 
with Crohn's disease and the presence of antibodies to viruses, bacteria 
and tissue components are reviewed. 
Chapter 3 deals with the presence of serum agglutinins to coccoid anaer-
obes in patients with Crohn's and other diseases. 
Relationships between agglutination reactions and clinical and laboratory 
features in patients with Crohn's disease and ulcerative colitis are the 
subject of Chapter 4. 
In Chapter 5 the results are reported of studies on the nature and prop-
erties of the antibodies, in particular their effector functions. 
In Chapter 6 logical interpretation of laboratory results is discussed 
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and this chapter serves as an introduction to Chapter 7, in which the 
use of the agglutination reactions as a diagnostic tool is described. 
Chapter 8 is a general discussion on the relevance of the findings for 
the understanding of the aetiology of Crohn's disease. 
REFERENCES 
Wensinck, F. (1975) The faecal flora of patients with Crohn's disease. 
Antonie van Leeuwenhoek 41, 214-215 
Wensinck, F. (1976) Faecal flora of Crohn's patients. Serological dif-
ferentiation between Crohn 1 S disease and ulcerative colitis. In: The 
management of Grahn's disease. Excerpta Medica, Amsterdam, pp. 103-105 
2 
chapter 
REVIEW OF RECENT LITERATURE ON THE PRESENCE OF MICROBIAL AGENTS AND 
ANTIBODIES IN PATIENTS WITH GROEN'S DISEASE 
VIRUSES 
Transmissible agents. In 1970 Mitchell and Rees described an experiment 
in which homogenates from Crohn gut or lymph-node tissue were inoculated 
into the footpads of normal and immunologically deficient mice. In both 
groups of mice, epithelioid and giant-cell granulomas were seen in the 
footpads, in 63% a month and in 33% 169 to 500 days after inoculation. 
One of the 58 mice given non-Crohn's lymph-node homogenates showed these 
characteristics after one month and none of the 48 surviving mice after 
169-500 days. These experiments were continued by Cave et al. (1973). 
Six rabbits were inoculated intra-ileally with tissue homogenates from 2 
patients with Crohn's disease. The control group consisted of 3 rabbits. 
Tissues for histological assessment were obtained at 3, 6 and 9 months. 
All animals were killed after 10 months. Results were inconsistent, but 
most rabbits inoculated with Crohn's tissue homogenates showed a granulo-
matous response after various intervals in at least one of the biopsies. 
Bolton et al. (1973) inoculated homogenates, fresh and sterilized, of 
diseased and normal bowel from 7 patients with Crohn's disease into 96 
rats, 69 guinea-pigs and 130 mice. Histological examination was perfor-
med 6-9 weeks and 6-8 months after inoculation. No sarcoid-like granulo-
mas were found in any biopsy, whether taken early or late. In 1975 Cave 
et aZ. reported mucosal ulceration, ileal thickening, abscess formation 
and granulomatous changes in rabbits, inoculated intramurally into the 
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intestine with 0.2 or 100 nm filtrates of homogenate of fresh ileum or 
colon from each of 6 patients with Crohn's disease. Moreover, a succes-
ful first passage was achieved from 6 of 11 rabbits. This was followed 
by completely negative results reported by Heatley et a~. (1975) in 17 
mice, 67 rats and 7 rabbits, inoculated with tissue homogenates from 
17 patients with Crohn's disease. Taub et aZ. (1976) inoculated foot-
pads of 13 mice with tissue homogenates from patients with Crohn's 
disease. Twelve showed epithelioid granulomas at the injection site 25 
days later and these were most numerous in mice injected with actively 
inflamed granulomatous material. Homogenates taken from patients with 
ulcerative colitis and from control patients undergoing resections for 
unrelated diseases produced granulomas in 4 of 4 and 4 of 9 instances, 
respectively. In mice inoculated with Crohn's disease tissue homogenates, 
granulomas were no longer identifiable 150 days after injection. Donnel-
ly et a~. (1977) reported experiments in which rabbits were inoculated 
with homogenates of normal and Crohn's affected human bowel tissues. 
Crohn's like changes were found in 11 of 27 rabbits after 6 months, but 
12 months after injection the rabbit bowel had reverted to normal. More-
over, the addition of ampicillin to the homogenates prevented the appear-
ance of the Crohn's like changes. Contradictory reports continue to ap-
pear. Simonowitz et aZ. (1977) only observed changes in the bowel wall of 
rabbits receiving Crohn's disease inoculum. However, the characteristic 
features of Crohn's disease were not reproduced. Bergstrand and HolmstrOm 
(1978) reported negative results with 0.2 nm filtrates in rats but Cave 
et aZ. (1978) again reported positive results in normal and immunodefic-
ient mice with crude and cell free filtrates of Crohn's tissues. The same 
authors (Cave et aZ., 1979) recently had to admit, however, that two fig-
ures in their latest paper showed a leiomyosarcoma of uterine origin and 
a lymphoma of aging mice rather than granulomatous reactions and they em-
phasized the difficulties inherent in interpreting histologic experiences 
in long-term animal studies. 
Electron microscopy. Gitnick and Rosen (1976) characterized viral partic-
les isolated from ileal filtrates of patients with Crohn's disease; con-
trol filtrates showed no evidence of viral agents. The mean diameter of 
the particles was 30 nm. The physical chemical properties and the electron 
microscopic appearance were consistent with those of a picornavirus. Rie-
mann (1977) found virus-like particles, with diameters ranging from 30-70 
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nm, in biopsies of 7 of 9 patients with Crohn's disease of the colon. 
Tissue culture and immunofluorescence methods. Farmer et aZ. ( 1973) in-
vestigated cytopathogenic effects in tissue cultures of tissue specimens 
from 4 patients with Crohn's disease and 6 with ulcerative colitis. Tis-
sues were also investigated with indirect fluorescent antibody tests and 
electron microscopy. In tissues from one of the patients with Crohn's 
disease and 3 of those with ulcerative colitis, cytomegalovirus was dem-
onstrated. Whorwell et aZ. (1977) found cytopathogenic effects of 220 nm 
filtrates of intestinal resections from 6 of 10 patients with Crohn's 
disease, whereas control filtrates had no effect.The agent appeared to 
be a RNA virus, 55-60 nm in diameter, probably belonging to the reovirus 
group. Indirect immunofluorescence for antigens of rotavirus in Crohn's 
disease tissue yielded positive results with tissues of 5 from 9 patients. 
Since fluorescence could not be blocked with specific calf antibody, the 
authors concluded that a reaction with viral antigen in the tissue was 
unlikely and that the observed phenomenon was not specific. 
Viral antibodies. In sera of patients with Crohn's disease, normal titres 
of antibodies to Epstein-Barr virus were found (Grotsky et aZ., 1970; 
Kane & Nye, 1971). Farmer et aZ. (1973) found normal titres of antibody 
to cytomegalovirus in patients with Crohn's disease, but a higher freq-
uency of antibody and higher titres were found in ulcerative colitis pat-
ients. DeGroote et aZ. (1977) found a higher frequency (90%) of antibodies 
to rotavirus in patients with Crohn's disease than in those with ulcerat-
ive colitis (68%) and the control group (75%). No differences were seen 
between patients with Crohn's disease and controls in antibody titres to 
coxsackievirus 84 and poliovirus 2. Greenberg et aZ. (1978) found compar-
able antibody titres in patients with Crohn's disease and controls to 
rotavirus and norwalkvirus. Korsmeyer et aZ. (1976) demonstrated antibodies 
to double-stranded RNA in 23% of the patients with Crohn's disease and 12% 
of those with ulcerative colitis. DeHoratius et aZ. (1978) observed that 
serum from patients with inflammatory bowel disease and their unaffected 
spouses bound significantly more synthetic single and double-stranded RNA 
than did serum from age-matched controls and their spouses. The authors 
interpreted these findings as indirect support for the presence of RNA 
viruses in patients with inflammatory bowel disease and the transmission 
of such agent to close personal contacts. 
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BACTERIA 
Electron microscopy. In 1971 Aluhiware described results of an electron 
microscopic study of colonic tissues from 16 patients with Crohn's dis-
ease. In 6, intramural clusters of bacteria were seen in the deeper lay-
ers of the colon with intact epithelium and minimal inflammatory changes. 
The bacteria were not identified, the appearance varying from degenerat-
ing bacilli to coccoid organisms. The organisms were not seen in any of 
the normal colons or in any of those with ulcerative colitis and intact 
epithelium. 
Cultural methods and immunofluorescence methods. Parent and Mitchell 
(1978) isolated cell wall-defective variants of pseudomonas-like bacteria 
from filtrates of homogenized bowel tissues and lymph-nodes, obtained 
from 8 patients with Crohn's disease. Positive results were obtained on-
ly if the filtrates were cultured in hypertonic media. Conventional bac-
teriological cultures and all cultures from 9 patients with ulcerative 
colitis and 20 patients without inflammatory bowel disease yielded negat-
ive results. Burnham et aZ. (1978) cultured mesenteric lymph-nodes from 
patients with inflammatory bowel disease and controls on mycobacterial 
media. A node from one out of 27 patients with Crohn's disease yielded 
a strain of MYcobacterium kansasii. Cultures from 22 other patients with 
Crohn's disease, 7 out of 13 with ulcerative colitis and one out of 11 
control subjects yielded pleomorphic organisms with the electron micros-
copic appearance of cell wall-deficient organisms. These organisms could 
not be further characterized. Whorwell et aZ. (1978), however, found no 
evidence by indirect immunofluorescence methods, for the presence of 
Pseudomonas maZtophiZia and MYcobacterium kansasii in tissues from 9 pat-
ients with Crohn's disease and 4 with ulcerative colitis. 
Bacterial antibodies. Thayer et aZ.(1969) studied the incidence of anti-
bodies to 2 strains of Escherichia coli, 0:14 and 0:119. An indirect 
haemagglutinating antibody titre of ~16 was considered positive. Posit-
ive results for E. coZi 0:14 occurred with sera of 39% of the patients 
with Crohn's disease, 33% of the patients with ulcerative colitis and 
3% of the sera of patients with various diseases. There was no correla-
tion between site of the disease process and the incidence of positive 
titres. Studies with E. coli 0:119 were negative in Crohn's disease. 
Brown and Lee (1971) using a radioimmunological method found normal anti-
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body titres against an unidentified E. coli strain in patients with 
Crohn's disease. In 1974 the same authors found slightly increased titres 
to enterococci in patients with Crohn's disease as well as in those with 
ulcerative colitis. Marked elevations of antibody titres to Bacteroides 
fragilis were found in both diseases and the titres correlated with the 
seYerity of disease and the presence of pyogenic complications. 
Tabaqchali et al. (1978) studied the incidence of agglutinating antibodies 
to 159 strains of E. coli in 16 patients with Crohn's disease and 14 with 
ulcerative colitis. Titres of ~200 were considered positive. In the sera 
of patients with Crohn's disease, antibodies were demonstrated to 0-30 
strains (median 10) and in those from patients with ulcerative colitis 
to 0-26 strains (median 5). Antibody titres in both diseases were similar. 
The highest titres were found in the IgM fractions, but IgG fractions 
yielded positive reactions as well. No specific 0-serotypes were associ-
ated with either disease and no correlations were seen between the num-
ber of agglutinins to E. coli and the site and severity of the disease 
or type of therapy. These results are different from those of Thayer et 
al. (1969), who found an increased incidence of antibodies to E. coli 
0:14 in patients with inflammatory bowel disease. 
Parent et al. (1978) investigated with an indirect immunofluorescence 
technique the incidence of antibodies to pseudomonas-like cell wall 
deficient bacteria, previously cultured from tissues of patients with 
Crohn's disease (Parent & Mitchell, 1978). In patients with Crohn's 
disease, 15 out of 17 had titres of ~80. In 7 patients with ulcerative 
colitis and 10 healthy controls titres were found up to 40. White et al. 
(1978) found with indirect immunofluorescence in 9 out of 11 patients 
with Crohn's disease and 8 out of 10 with ulcerative colitis antibody 
titres of ~20 to MYcobacterium kansasii. The tests were negative in 22 
control subjects. Helphingstine et al. (1979) found by counterimmuno-
electrophoresis in 12 out of 12 sera from patients with Crohn's disease 
antibodies to a heat-extracted antigen of Bacteroides vulgatus. In a 
mixed group of patients with inflammatory bowel disease, 59% positive 
reactions were seen compared to 32% in a healthy control group. The 
antibodies occurred in low titres of about 4 and were predominantly of 
the IgM class. With antigens from 6 other Bacteroides strains no dif-
ferences were found between the groups. 
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CHLAMYDIA 
Schuller et al.(1979) detected antibodies to Chlamydia trachomatis of 
predominantly LGV type 2 in 69% of sera from patients with Grahn's dis-
ease, in 10% of those with other gastrointestinal diseases and in 2% of 
healthy control sera. These results were not confirmed by Taylor-Robin-
son et al. (1979) who found antibodies to Chlamydia trachomatis in pat-
ients with Crohn's disease and ulcerative colitis with incidences of 
14.5 and 21.7%, respectively, resembling the incidence in a healthy, 
non-venereal-disease population. In no case was antibody directed spec-
ifically to the LGV types. Swarbrick et al. (1979) found antibodies to 
Chlamydia trachomatis types A-K or 207 in only 7% of patients with 
Crohn's disease, in 12% of those with ulcerative colitis and in 14% of 
patients with other digestive diseases. Again, none had antibodies to 
LGV types or Chlamydia psittaci. 
The results obtained by Taylor-Robinson et al. (1979) and Swarbrick et 
al. (1979) suggest that antibodies to Chlamydia trachomatis, LGV types 
included, and Ch~dia psittac~ do not occur more commonly in patients 
with inflammatory bowel disease than in control populations. 
ANTIBODIES TO TISSUES, CELLS AND DIETARY PROTEINS 
Antibodies to homologous tissues. In 6-25% of the sera from patients 
with Crohn's disease, antibodies to connective tissue and reticulin were 
demonstrated (Alp & Wright, 1971; ~lagalhaes et al., 1974; Eterman & 
Feltkamp, 1978). Results obtained in other diseases suggest that these 
antibodies were secondary to tissue damage or absorption of dietary 
antigens. Normal incidences were found for antibodies to human colon, 
smooth muscle, mitochondria, thyroglobulin, thyroid cytoplasma, gastric 
parietal cells and the nuclei of cells (Perrett et al., 1971). Walker 
(1978) studied sera of patients with inflammatory bowel disease and con-
trols for the presence of antibodies to buccal mucosa with an immuno-
fluorescence technique. Direct staining with polyvalent antiserum show-
ed no deposit of antibodY in normal, Crohn 1 s disease and ulcerative col-
itis buccal mucosa. When the mucosae were incubated with homologous serum, 
a perinuclear fluorescence was seen only when both mucosa and serum were 
obtained from patients with Crohn's disease. These studies were extended 
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by Matthews et aL (1979) who found positive results in only 2 out of 
9 patients with Crohn's disease with autologous sera and 4 out of 11 
with the use of heterologous sera. These antibodies also reacted with 
normal epithelial tissue and also occurred in one out of 4 patients 
with ulcerative colitis. 
Antibodies to lymphocytes. Antibodies to lymphocytes have been demon-
strated in a wide variety of human disease states, including connective 
tissue diseases and viral and bacterial infections. They also occur 
in healthy subjects, during pregnancy and following vaccinations (see 
references of Strickland et aL , 1975). They were detected in 40% of 
the patients with Crohn's disease and ulcerative colitis (Strickland et 
aZ. , 1975). The antibodies were reactive with determinants of both T-
and 8-lymphocytes. An increased prevalence of these antibodies was seen 
in family members and household contacts of patients with inflammatory 
bowel disease (Korsmeyer et aZ. , 1975). The relevance of these lympho-
cytotoxic antibodies in patients with inflammatory bowel disease remains 
a matter of speculation. The authors suggest that they may indicate an 
exposure of probands and their family members to a common environmental 
agent. 
Antibodies to heterologous tissues. Carlsson et aZ. (1977) found that 
61% of their patients with Crohn's disease had haemagglutinating anti-
bodies in titres of ~16 to colon antigen from germ-free. rats. These 
antibodies also occurred in increased frequencies (47 to 69%) in other 
diseases like ulcerative colitis, salmonellosis, polyposis coli and 
their family members, gastroenteritis, irritable colon, liver cirrhosis 
and urinary tract infections. In other, non-gastrointestinal diseases 
and healthy controls the percentages of positive reactions were 35% and 
13%, respectively. The results do not allow simple interpretation. The 
colon antigen probably contains several antigenic determinants, some of 
which in common with E. eoZi 0:14 (Perlmann et aL , 1967). 
Antibodies to dietary proteins. Taylor et aZ. (1964) found normal fre-
quencies of antibodies to a fraction of gluten. Eterman and Feltkamp 
(1978), however, demonstrated antibodies to gluten in 52% of patients 
with Crohn 1 s disease. Highest frequencies were found in children with 
untreated coeliac disease (100%), and in half of the adults with untreat-
ed disease. In patients on a gluten-free diet these percentages decreas-
ed to 87 and 32, respectively. High percentages were also found in cys-
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tic fibrosis (42%), recurrent diarrhoea (37%), dermatitis herpetiformis 
(18%) and ulcerative colitis (18%). These results were confirmed by 
Davidson et al. (1979) who also found that maize antibodies occurred in 
33% of patients with Crohn's disease as well as in those with ulcerative 
colitis (50%), coeliac disease (44%), and healthy subjects (14%). 
Falchuk and lsselbacher (1976) found antibodies to bovine serum albumin 
in 86% of patients with Crohn's disease, in 93% of those with ulcerative 
colitis, in 5 out of 5 with untreated coeliac disease and in healthy 
subjects (43%). The most likely explanation of these findings is that 
increased frequencies of dietary antibodies result from an increased 
absorption of dietary proteins as a consequence of damage of the intes-
tinal mucosa. 
CONCLUSIONS 
The results of experiments on the transmissibility of Crohn's disease 
are contradictory and no general conclusion can be drawn. It appears 
likely, however, that the capacity to induce a granulomatous inflam-
matory response is not specific for Crohn's disease or otherwise in-
flamed tissues. The relevance of these findings to the aetiology of 
Grahn's disease is therefore doubtful. 
With electron microscopy, cultural methods and indirect immunofluores-
cence, the presence of a variety of viruses has been demonstrated in 
tissues of patients with inflammatory bowel disease. None of these in-
vestigations, however, provide strong evidence for a viral aetiology 
of Crohn's disease. 
Studies on the presence of bacteria in Crohn's disease tissues have· 
also yielded contradictory results. Neither from results obtained with 
cultural methods, nor from serological studies, does a bacterial aetio-
logy seem likely. Results of studies in which a wide variety of tissue 
and dietary antibodies were demonstrated suggest that these antibodies 
are secondary to tissue damage, increased absorption or cross reactions. 
Fro~ the many studies mentioned it can be concluded that in patients 
with Crohn's disease as well as in other gastrointestinal diseases, 
antibodies to a wide variety of antigens, especially those present 
in the intestine, are found frequently. 
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chapter 
SERUM ANTIBODIES TO EUBACTERIUM AND PEPTOSTREPTOCOCCUS SPECIES IN 
CROHN'S AND OTHER DISEASES,. 
INTRODUCTION 
The faeces of patients with Grahn's disease of the ileum has been shown 
to contain higher numbers of anaerobic gram-negative rods and of gram-
positive coccoid anaerobes than that of healthy subjects. Duration of 
illness and ileocaecal resection had no effect on flora composition 
and this suggests that the flora may be abnormal before the disease 
becomes manifest (Wensinck et al., 1980). 
In a preliminary study it has been found that Crohn's sera agglutinate 
a strain of Eubacter-ium contortum more frequently than sera from pat-
ients suffering from other diseases and healthy subjects (Wensinck, 1975; 
1976). Since then, some 25 isolates belonging to species of Eubacterium 
and Peptostreptococeus have been tested and, except for a few strains 
that were not agglutinated at all, they were agglutinated by a higher 
percentage of sera from patients with Crohn's disease than from healthy 
subjects. Four strains were eventually selected on the basis of their ca-
pacity to discriminate between patients with Crohn's disease and healthy 
subjects by means of agglutination reactions. 
In this chapter the results are presented of these agglutination reac-
tions. From these results the a posteriori probability of Crohn's dis-
ease (see Chapter 7) is calculated in patients with Crohn's disease, 
ulcerative colitis, various other diseases and healthy subjects. 
Subsequently, sera submitted for diagnosis have been interpreted in the 
,.) This chapter forms part of a paper by Wensinck and Van De Merwe, sub-
mitted for publication. 
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same way and the results with these sera are also given. 
MATERIALS AND METHODS 
Sera were provided by physicians from various hospitals (see acknowled-
gements). Requests for serum included specifications as to certain clin-
ical features or laboratory parameters. Control patients suffering from 
other diseases (Tab 1 e 1), ca 11 ed 11 COntro 1 diseases 11 , were considered by 
the physicians to have the classical disease. The diagnosis was uncertain 
Table 1. Diseases of eontroZ patients~ with eertain eharaeteristies 
INTESTINAL TRACT AND LIVER 
acute appendicitis: uneventful] postoperative course 
carcinoma of large bowel 
chronic diarrhoea: of unknown origin, in children with median age of5 yrs (1-15) 
coeliac disease: treated and untreated patients 
irritable bowel syndrome* 
ulcerative colitis: group similar to that of Chapter 4 
chronic active liver disease: all patients HBsAg positive 
cirrhosis of liver: mostly due to alcohol abuse 
primary biliary cirrhosis: antimitochondrial antibodies in all patients 
schistosomiasis: patients from The Netherlands and Ethiopia 
OTHER 
ankylosing spondylitis: HLA-27 positive; no suspicion of bowel disease 
atopy*: out-patients and students with a history of atopy 
rheumatoid arthritis: rheumatoid factor positive 
leprosy: all patients under medical treatment 
pulmonary tuberculosis*: all patients under medical treatment 
sarcoidosis*: groups I-IV present 
bronchial carcinoma 
haematological malignancies: nearly equal numbers of patients with 
Hodgkin's disease and lymphosarcoma 
*) Studied with strains Me 44 and C 18 only. 
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in many patients from whom serum was submitted for diagnostic purposes 
and detailed information was requested in all cases with positive 
serological results. 
Crohn's disease and healthy subjects. All patients (n = 125) were under 
treatment at the Depts. of Internal t1edicine II or Surgery, University 
Hospital Dijkzigt, Erasmus University, Rotterdam. Healthy subjects (n = 
100) were blood donors (Red Cross Transfusion Service, Rotterdam). The 
groups of patients and healthy subjects are similar to those in Chapters 
4 and 7. 
Sera submitted for diagnosis. This group consisted of all sera received 
during June, July and August, 1978. 
Bacteria. From the four strains tested, three were isolated from the 
faeces of patients with Crohn 1 s disease as described by Wensinck et aZ. 
(1980), code numbers Me 44, Me 46 and Me 47. One strain (C 18) was re-
ceived from Dr Moore (The Virginia Polytechnic Institute and State Uni-
versity, Anaerobe Laboratory, Blacksburg, USA). Some characteristics of 
the strains are given in Table 2. Two strains (Me 44 and Me 47) were 
identified as Eubacterium contortum, one (Me 46) as Eubacterium rectaZe 
and one (C 18) as Peptostreptoeoccus produetus. 
Agglutinating suspensions. Suspensions were prepared from cultures in 
anaerobic broth (see Hensinck et al., 1980) grown for 24-48 h at 37°C. 
Formaldehyde solution was added to a final concentration of 0.5% and, 
after incubation for 18 h at 37°C the bacteria were washed twice and 
resuspended in 0.9% (w/v) saline with 0.01% (w/v) sodium ethylmercuri-
thiosalicylate. Cell density was adjusted to about 5 X roB bacteria per 
ml and pH to 6.8 - 7.0; pH of freshly prepared suspensions had to be re-
adjusted after 3-4 days and the suspensions were checked monthly for 
contamination. 
Agglutination test. Sera were tested within 3 days after collection. Two 
drops of serum and one drop of suspension were thoroughly mixed with a 
platinum loop and the slide was shaken (150 rpm) on the platform of a 
rotary mixer (Mini-Shaker, KUhner AG, Basel, Switzerland). Results were 
scored after 5 min as negative (0) or positive (1, 2 or 3, according to 
strength). With strongly positive sera, the agglutinate consisted of a 
clump and the surrounding fluid was clear. Inactivation of complement 
(30 min at 560C) or storage at -40°C had no effect on the test. 
Statistical methods. Results were compared using x2 -tests withYates 1 cor-
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Table 2. Characteristics of the anaerobic gram-positive coccoid rods 
STRAIN 
Me 44 Me 47 Me 46 c 18 
arabinose + + + + 
xylose + + + + 
fructose + + + + 
glucose + + + + 
mannose + 
cellobiose + + 
1 actose + + + 
maltose + + + + 
sucrose + + + + 
trehalose + 
melezitose + 
raffinose + + + + 
starch 
amygdalin 
esculin (hydrolysis) + + + 
salicin + + + 
erythri to 1 
mannitol 
sorbitol + 
gas + + + 
final pH 4.7 5.4 5.0 4.3 
fermentation products E,A,F E,A nB,L A,F 
+ acid produced; no acid produced 
E ; ethanol 
A acetic acid 
L ; lactic acid 
nB; normal butyric acid 
F ; formic acid 
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rection. Because it was evident that strength of agglutination should 
be considered when the four strains were used as a diagnostic set~ an 
interpretation of test results based on the weight of each strain has 
been worked out. The result with a given serum (scored as 0, 1, 2 or 3 
for each strain) was used to estimate the a posteriori probability that 
the patient suffers from Crohn's disease. Details of the method are des-
cribed in Chapter 7. In the present chapter, sera with test results 
giving an a posteriori probability ~0.95 were considered positive. 
RESULTS 
Results are presented under three headings: (1) patients with Crohn's 
disease and healthy subjects; (2) "control diseases" and (3) sera sub-
mitted for diagnosis. 
Crohn's disease and healthy subjects. From the data in Tables 3-6 it is 
evident that the four strains were agglutinated more frequently by sera 
from patients with Crohn's disease than by those from healthy subjects. 
Fifty-four percent of sera from patients with Crohn's disease were posit-
ive (a posteriori probability ~0.95) and all sera from healthy subjects 
negative (Table 7). The test with four strains, thus has a sensitivity 
of 54% and a specificity of nearly 100%. 
11 Control diseases 11 • Table 3 shows that strain Me 44 (Eubacterium cantor-
tum) was agglutinated by sera from control patients with percentages not 
significantly different from the normal value. The other strain of Eubac-
terium eontortum (Me 47) was agglutinated more frequently by sera from 
patients with large bowel carcinoma but percentages of other "control 
diseases" were not significantly different from that in healthy subjects 
(Table 4). Strain Me 46 (Eubacterium reetale) was also agglutinated more 
frequently by sera from patients with colonic carcinoma. It also showed 
a higher than normal percentage in ulcerative colitis patients (Table 5); 
the percentage was however much lower than in patients with Crohn's dis-
ease (P < 0.001). Sera from patients with various "control diseases" 
agglutinated Peptostreptoeoccus produetus (strain C 18) more frequently 
than sera from healthy subjects (Table 6) but in all cases the percen-
tages were significantly lower than in Crohn's disease. It should be noted 
that results in Ethiopian controls were normal and that sera from atopic 
out-patients agglutinated C 18 more frequently than normal but those 
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Table J. Agglutination of Eubacterium contortum (strain Me 44) 
% EDSitive* no. of Eatients 
INTESTINAL TRACT AND LIVER 
acute appendicitis 5 21 
carcinoma of large bowel 19 52 
chronic diarrhoea (in children) 5 20 
coeliac disease 23 44 
irritable bowel syndrome 10 20 
ulcerative colitis 15 48 
chronic active liver disease 19 27 
cirrhosis of liver 21 38 
primary biliary cirrhosis 5 20 
schistosomiasis 26 68 
(Ethiopian control sera) (30) (23) 
OTHER 
ankylosing spondylitis 21 75 
atopy 
out-patients 28 29 
students 21 34 
rheumatoid arthritis 6 51 
1 eprosy 25 85 
pulmonary tuberculosis 21 42 
sarcoidosis 23 80 
bronchial carcinoma 16 58 
haematological malignancies 10 80 
Crohn's disease 62(<0.001) 125 
healthy subjects 15 100 
~) P-value of difference with healthy subjects in parentheses; P-values 
only given when ~0.05. 
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TabZe 4. AggZutination of Eubacterium contortum (strain Me 47) 
% positive* no. of patients 
INTESTINAL TRACT AND LIVER 
acute appendicitis 14 21 
carcinoma of large bowel 15(=0.05) 39 
chronic diarrhoea (in children) 5 20 
coeliac disease 11 37 
irritable bowel syndrome 
ulcerative colitis 4 48 
chronic active liver disease 15 27 
cirrhosis of liver 10 21 
primary biliary cirrhosis 5 20 
schistosomiasis 
OTHER 
ankylosing spondylitis 8 24 
atopy 
rheumatoid arthritis 0 19 
leprosy 14 28 
pulmonary tuberculosis 
sarcoidosis 
bronchial carcinoma 5 20 
haematological malignancies 5 22 
Crohn's disease 37(<0.001) 118 
healthy subjects 4 100 
,.) P-value of difference with healthy subjects in parentheses; P-values 
only given when ~0.05. 
-: not tested. 
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Tcible 5. Agglutination of Eubacterium rectale (stro:in Me 46) 
% positive* no. of eatients 
INTESTINAL TRACT AND LIVER 
acute appendicitis 5 21 
carcinoma of large bowel 10(<0.05) 41 
chronic diarrhoea (in children) 5 20 
coeliac disease 8 38 
irritable bowel syndrome 
ulcerative colitis 17(<0.001) 48 
chronic active liver disease 7 27 
cirrhosis of liver 8 25 
primary bi 1 i ary cirrhosis 10 20 
schistosomiasis 4 48 
OTHER 
ankylosing spondylitis 8 24 
atopy 
rheumatoid arthritis 7 30 
1 eprosy 6 31 
pulmonary tuberculosis 
sarcoidosis 
bronchial carcinoma 0 20 
haematological malignancies 0 22 
Crohn's disease 49(<0.001) 124 
healthy subjects 1 100 
*) P-value of difference with healthy subjects in parentheses; P-values 
only given when ~0.05. 
-: not tested. 
23 
Table 6. Agglutination of Peptostreptococcus productus (strain C 18) 
% positive* no. of eatients 
INTESTINAL TRACT AND LIVER 
acute appendicitis 10 21 
carcinoma of large bowel 12 52 
chronic diarrhoea (in children) 0 20 
coeliac disease 9 44 
irritable bowel syndrome 5 20 
ulcerative colitis 21(<0.01) 48 
chronic active liver disease 7 27 
cirrhosis of liver 26(<0.001) 38 
primary biliary cirrhosis 5 20 
schistosomiasis 41 ( <0. 001) 68 
(Ethiopian control sera) (13) (23) 
OTHER 
ankylosing spondylitis 39(<0.001) 40 
atopy 
out-patients 34(<0.001) 29 
students 3 34 
rheumatoid arthritis 6 34 
leprosy 29(<0.001) 59 
pulmonary tuberculosis 19(<0.05) 42 
sarcoidosis 7 29 
bronchial carcinoma 2 49 
haematological malignancies 3 30 
Crohn • s disease 55(<0.001) 125 
healthy subjects 5 100 
,.) P-value of difference with healthy subjects in parentheses; P-values 
only given when ~0.05. 
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Table 7. Percentage of positive sera with combined test 
INTESTINAL TRACT AND LIVER 
acute appendicitis 
carcinoma of large bowel 
chronic diarrhoea (in children) 
coeliac disease 
irritable bowel syndrome 
ulcerative colitis 
chronic active liver disease 
cirrhosis of liver 
primary biliary cirrhosis 
schistosomiasis 
OTHER 
ankylosing spondylitis 
atopy 
rheumatoid arthritis 
1 eprosy 
pulmonary tuberculosis 
sarcoidosis 
bronchial carcinoma 
haematological malignancies 
Crohn 1 s disease 
healthy subjects 
% positive* no. of patients 
5 
5 
5 
8(<0.05) 
12(<0.001) 
7 
8(=0.05) 
0 
8 
7 
6 
0 
5 
54(<0.001) 
0 
21 
41 
20 
38 
48 
27 
25 
20 
26 
28 
31 
20 
22 
118 
100 
*) Positive: posterior probability ~0.95 with prior probability = 0.5. 
P-value of difference with healthy subjects in parentheses; P-values 
only given when ~0.05. 
- not tested with four strains. 
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Table 8. Sera sUbmitted for diagnosis 
Period 
Total number of sera 
Positive* 
Clinical diagnosis 
Crohn 1 s disease 
probable Crohn's disease 
colitis (undefined) 
presenting symptoms: 
ana 1 fistulae 
diarrhoea 
other 
coeliac disease 
carcinoma 
growth retardation 
uncertain 
June, July and August, 1978 
517 
110 
68 (62%) 
16 (15%) 
13 (12%) 
9 (8%) 
4 
5 
4 (3%) 
1 
1 
1 
1 
,.) Posterior probability ~0.95 (prior probability = 0.5) 
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from atopic students did not. 
The percentages of positive sera as calculated from the results with 
four strains are shown in Table?. The percentage was higher than nor-
mal in cirrhosis of liver, coeliac disease and ulcerative colitis but 
significantly lower than in Crohn 1 S disease. 
Sera submitted for diagnosis. From the sample representing about one 
quarter of the sera received in 1978, 21% was positive (Table 8 ). In 62 
%of the positive cases, the diagnosis Crohn 1 s disease had been establis-
hed, in 15% Crohn's disease was likely, in 12% colitis was undefined and 
in 8% anal fistulae or diarrhoea suggested inflammatory bowel disease. 
In 3% of the positive cases, clinical data appeared incompatible with 
the diagnosis of Crohnrs disease. This percentage is acceptable as sera 
were considered positive when the (a posteriori) probability of Crohn's 
disease was~ 0.95, implying that 5% of positive results may occur in 
patients without Crohn 1 S disease. 
DISCUSSION 
The finding that intestinal coccoid anaerobes are agglutinated more 
frequently by sera from patients with Crohn's disease than from healthy 
subjects is in line with data showing that these patients produce anti-
bodies to a wide range of food and microbial antigens (see Chapter 2). 
This may be explained by assuming that conditions for antibody produc-
tion are favourable in the inflamed mucosa with dense infiltrates of 
lymphocytes. In the case of coccoid anaerobes, the high numbers present 
in the intestinal microflora (Wensinck et aZ., 1980) may promote anti-
body production. 
In the present study, 17% of patients with Crohn's disease did not ag-
glutinate any of the four coccoid strains and 54% were positive with a 
a posteriori probability of~ 0.95. In a study of correlations between 
agglutination reactions and nosographic characteristics of patients with 
Crohn's disease and ulcerative colitis (Chapter 4) it was found that ag-
glutination was positively correlated with colonic localization of Crohn's 
disease, the presence of fistulae and with levels of serum immunoglobul-
ins. 
There is one striking difference between the studies on antibody produc-
tion (Chapter 2) and our results. Antibodies to the various food and 
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microbial antigens were present in both Crohn 1 S and ulcerative colitis 
patients but, with the coccoid anaerobes, results in these diseases were 
significantly different. From the groups of patients with Crohn's dis-
ease, 54% were positive and from the patients with ulcerative colitis 
12%. Moreover, the percentage of sera that were negative with all 
strains was only 17% in Crohn 1 S disease, compared to 65% in ulcerative 
colitis and 7g% in healthy subjects. In view of the well-known difficul-
ties with the differential diagnosis of Crohn's disease of the colon 
and ulcerative colitis (Glatzer et a~-, 1970; Dyer & Dawson, 1970; Kirs-
ner, 1975; Brandes & Eulenburg, 1976), we feel that misdiagnosis should 
be considered when serological reactions turn out to be positive in pat-
ients presumed to suffer from ulcerative colitis. 
From the 11 Contro 1 diseases 11 , coeliac disease and cirrhosis of liver show-
ed slightly higher percentages of positive sera than healthy subjects. 
Cirrhosis of liver, schistosomiasis, ankylosing spondylitis, atopy (out-
patients), leprosy and pulmonary tuberculosis had more C 18 positive 
sera than healthy subjects. The agglutination of strain C 18 was correla-
ted with lgG levels in patients with Crohn's disease and, therefore, the 
frequent agglutination of C 18 in these "control diseases" may be due to 
the hyperimmunoglobulinaemia which occurs in a rather high number of pat-
ients suffering from schistosomiasis (Camus eta~., 1977), leprosy (see 
Bullock, 1971) and hepatic diseases (Osserman & Takatsuki, 1963; Zawadzki 
& Edwards, 1970; Triger & Wright, 1973). C 18 reactivity was increased 
in out-patients but not in atopic students, who were not under medical 
treatment at the time of blood collection. The increase of IgG levels, 
known to occur during hyposensitization (Devey eta~., 1976), may be 
responsible for the different results in atopic subjects. Antibody prod-
uction to the other strains was less (Me 44) or not (Me 46 and Me 47) 
correlated with lgG levels in patients with Crohn's disease, but with 
a more specific characteristic like fistulae. 
We conclude that antibodies to anaerobic coccoid rods are found much 
more frequently in Crohn's disease than in ulcerative colitis and other 
diseases. Using the interpretation of agglutination reactions as des-
cribed in Chapter 7, the percentage of false positive results of sera 
submitted for diagnosis, was found to be satisfactorily low. 
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ANTIBODIES TO EUBACTERIUM AND PEPTOSTREPTOCOCCUS, CLINICAL FEATURES AND 
LABORATORY PARAMETERS IN PATIENTS WITH CROHN'S DISEASE AND ULCERATIVE 
COLITIS 
INTRODUCTION 
In Chapter 3 it was shown that coccoid Eubacterium and Peptostreptoeoc-
c~s strains are agglutinated by many, but not all sera from patients 
with Crohn 1 S disease, whereas about 20% of the patients are negative 
with all strains on repeated testing. 
It is likely that the presence of the coccoid anaerobes in the faecal 
flora is a necessary determinant for the production of agglutinins, but 
other factors are also necessary or contributory. Therefore, the relation-
ship between the presence of agglutinins, and clinical and laboratory 
parameters (nosographic characteristics) was studied. 
MATERIALS AND METHODS 
Patients. During the period from October 1, 1975, to May 1, 1978, all 
consecutive patients with inflammatory bowel disease visiting the depart-
ments of internal medicine and surgery were studied. The data and blood 
obtained at the first presentation of the patient during the period ment-
ioned were used. The diagnoses of Crohn's disease and ulcerative colitis* 
*) Diagnoses were established by M. VAN BLANKENSTEIN and J. OEES, Depart-
ment of Internal Medicine II (Prof. Or M. FRENKEL), University Hospital 
Oijkzigt, Erasmus University, Rotterdam 
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were based on generally accepted criteria (Lennard-Janes et al., 1968; 
Ki rsner, 1975). Ore hundred-and-seventeen patients with Crohn' s disease were 
studied, 75 women and 42 men, median age 32 years (range 14-74). Fourty-
four had ileal disease, 26 ileocolonic and 47 colonic disease. Fifty-four 
patients had undergone intestinal resections. Twenty patients were receiv-
ing salicylazosulphapyridine (SASP), 10 were on corticosteroids and 8 on 
corticosteroid enemas. Fourty-six patients with ulcerative colitis were 
studied, 23 women and 23 men, median age 32 years (range 18-83). Eleven 
patients had undergone partial or total colonic resections. Twenty pat-
ients were receiving SASP, 2 were on corticosteroids and 2 on cortico-
steroid enemas. The group of healthy subjects consisted of 100 volunteers 
of the Red Cross Transfusion Service, Rotterdam, 57 men and 43 women. The 
median age was 35 years (range 23-64). 
Data. The following data were collected: age, sex, duration and localiza-
tion of disease, frequency of diarrhoea and the presence of macroscopic-
ally visible blood, abdominal pain, weight loss, arthritis, erythema no-
dosum, fever (temperature >38°C), fistulae and anal lesions. The follow-
ing determinations were performed in serum or blood: a1 -acid glycoprotein 
as an index of disease activity (Van De Merwe & Mol, 1977), !gA, !gG and 
lgM (see Chapter 5), albumin, haematocrit and agglutination reactions. 
Statistical methods. To compare results, non-parametric statistical meth-
ods were used, viz. the x2 -test with Yates 1 correction for continuity, 
Wilcoxon•s two-sample rank sum test, Spearman 1 S rank correlation test and 
the Yates-Cochran test. Probability values (P) were derived from two-
tailed tests. Some data were dichotomized for the calculations: agglutina-
tion reactions were considered either negative (0) or positive (1, 2 or 
3), diarrhoea was considered to be present when the patient had watery or 
at least twice daily loose stools and low haematocrit values were defined 
as <0.47 for men and <0.42 for women (Best et al., 1976). A posteriori 
probabilities of Crohn's disease were calculated as described in Chapter 
7 and the Crohn's disease activity index (COAl) was calculated according 
to Best et al., 1976. 
The number of statistical tests performed was 344 for Crohn's disease 
and 293 for ulcerative colitis. For both diseases the numbers of spurious-
ly significant results to be expected by coincidence and the numbers ob-
served are recorded in Table 1. From this table it is seen that in Crohn's 
disease the number of significant results is much higher than expected by 
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TohZe 1. Nwribers of ezpected and observed tests showing statistical 
significance in patients with Grahn's disease and uZcerative coZitis 
NUMBER OF TESTS WITH STATISTICAL SIGNIFICANCE 
CROHN 'S DISEASE ULCERATIVE COLITIS 
Si gni fi cance level expected observed expected observed 
p < 0.05 17.2 gg 14.7 18 
p < 0.025 8.6 74 7.3 11 
p < 0.01 3.4 54 2.9 7 
p < 0.005 1.7 45 1.5 4 
p < 0.0025 0.9 41 0.7 4 
p < 0.001 0.3 34 0.3 2 
p < 0.0005 0.17 26 0.15 1 
p < 0.00025 0.09 26 0.07 0 
p < 0.0001 0.03 21 0.03 0 
Total numbers of tests 344 293 
chance alone. In ulcerative colitis, on the other hand, the number of 
expected and observed results for P ~ 0.0025 were of the same order of 
magnitude. Therefore, for Crohn•s disease P < 0.05 and for ulcerative 
colitis P < 0.0025 are considered critical significance levels. 
RESULTS 
Relationships were studied between all nosographic characteristics. In 
the tables only statistically significant correlations are presented. 
Results with agglutination reactions will be given for Crohn's disease 
(A), for ulcerative colitis (B) and for healthy subjects (C). The fol-
lowing groups were compared: (D) Crohn's disease and healthy subjects 
(E) ulcerative colitis and healthy subjects (F) Crohn's disease and ul-
cerative colitis and (G) Crohn's disease of the colon and ulcerative 
colitis. A number of nosographic characteristics and their interrelations 
are only tabulated (see Appendix I) and will not be discussed. 
Frequency distributions of aggJutination reactions in patients with 
Crohn's disease, ulcerative colitis and healthy subjects, and in Crohn's 
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TabZe 2. Frequency distribution of aggZutination reactions in patients 
with Grahn's disease 3 uZeerative eoZitis and heaZthy subjects 
STRAIN RESULT OF AGGLUTINATION NUMBER OF SERA1 
CROHN'S ULCERATIVE HEALTHY 
DISEASE COLITIS SUBJECTS 
(n=ll7) (n=46) (n=100) 
Me 44 0 43 (37) 38 (83) 85 (85) 
1 12 (10) 2 (4) 5 ( 5) 
2 16 (14) 2 (4) 7 (7) 
3 46 (39) 4 (9) 3 (3) 
c 18 0 51 (44) 37 (80) 95 (95) 
1 15 (13) 4 (9) 3 (3) 
2 11 (9) 2 (4) 1 ( 1) 
3 40 (34) 3 (7) 1 ( 1) 
Me 46 0 59 (50) 39 (85) 99 (99) 
1 7 (6) 3 (7) 1 (1) 
2 7 ( 6) 1 (2) 0 (0) 
3 44 (38) 3 (7) 0 (0) 
Me 472 0 74 (64) 44 (96) 96 (96) 
1 9 (8) 1 (2) 2 (2) 
2 22 (19) 0 (0) 2 (2) 
3 10 (9) 1 (2) 0 (0) 
1) Percentages in parentheses. 
2) 115 Patients with Grahn's disease. 
disease according to site of disease are given in Tables 2 and 3. 
(A) Grahn's disease. Tables 4- 8 show that correlations were found 
between agglutination reactions and the presence of fistulae (strain 
C 18, Me 46 and f1e 47), colonic or ileocolonic disease (Me 44) and serum 
lgG and !gM (Me 44 and C 18). Mutual correlations were found between the 
agglutination reactions, except between Me 46 and Me 47. Agglutination 
of C 18 was weakly correlated with the presence of arthritis or erythema 
nodosum, whereas apparently contradicting negative correlations were 
seen between agglutination of Me 46 and both bloody stools and haemato-
crit value. Agglutination reactions were not correlated with any index 
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Table 3. Frequency distribution of agglutination reactions in patients 
with Crohn's disease aeeording to localization of disease 
STRAIN RESULT OF AGGLUTINATION NUMBER OF SERA1 
LOCALIZATION OF CROHN'S DISEASE 
ileum ileocolon colon 
(n=44) (n=26) (n=47) 
Me 44 0 22 (50) 7 (27) 14 (30) 
1 2 (5) 5 (19) 5 ( 11) 
2 7 ( 16) 4 (15) 5 ( 11) 
3 13 (30) 10 (38) 23 (49) 
c 18 0 23 (52) 11 (42) 17 ( 36) 
1 6 (14) 4 ( 15) 5 ( 11) 
2 4 (9) 1 (4) 6 (13) 
3 11 (25) 10 (38) 19 (40) 
Me 46 0 27 (61) 13 (50) 19 (40) 
1 5 ( 11) 0 (0) 2 (4) 
2 2 (5) 1 ( 4) 4 (9) 
3 10 (23) 12 ( 46) 22 (47) 
Me 47 0 26 (62)2 13 (50) 35 (74) 
1 4 (10) 2 (8) 3 (6) 
2 9 (21) 8 (31) 5 (11) 
3 3 (7) 3 ( 12) 4 (9) 
1) Percentages in parentheses. 
2) 42 Patients with ileal disease. 
of disease activity, like COAl, a 1 -acid glycoprotein or serum albumin 
1 evel . 
(B) Ulcerative colitis. A positive correlation was found between dura-
tion of disease and reactivity with strain Me 44 (P < 0.0005). 
(C) Healthy subjects. In the group of healthy subjects only a few deter-
minations were performed in serum: 01 -acid glycoprotein, IgA, IgG and 
lgM and the agglutination reactions. Out of 100 healthy subjects, 20 
showed at least one positive agglutination reaction. These subjects tend-
ed to have higher immunoglobufin levels, but this trend did not reach 
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Table 4. Nosographic characteristics correlated 
with agglutination of Me 44 in Grahn's disease 
CORRELATION WITH AGGLUTINATION OF ME 44x 
positive: ·IgM 
lgG 
•agglutination of C 18 
·agglutination of Me 46 
agglutination of Me 47 
negative: disease restricted to ileum 
x: p < 0.05; ·: p < 0.01 
Table 5. Nosographic characteristics correlated 
with agglutination of C 18 in Grahn's disease 
CORRELATION WITH AGGLUTINATION OF C 18x 
positive: ·fistulae 
arthritis/erythema nodosum 
lgM 
·lgG 
·agglutination of Me 44 
•agglutination of Me 46 
·agglutination of Me 47 
x: P < 0.05; • :P < 0.01 
Table 6. Nosographic characteristics correlated 
urith agglutination of Me 46 in Crohn 's disease 
CORRELATION WITH AGGLUTINATION OF ME 46x 
positive: fistulae 
•agglutination of Me 44 
·agglutination of C 18 
negative: bloody stools 
haematocrit 
x: p < 0.05; ·: p < 0.01 
Table ?. Nosographic characteristics correlated 
with agglutination of Me 4? in Grahn's disease 
CORRELATION WITH AGGLUTINATION OF ME 47x 
positive: fistulae 
x: p < 0. 05 
agglutination of Me 44 
agglutination of C 18 
Table 8. Nosographic characteristics correlated 
with posterior probability in Grahn's disease 
CORRELATION WITH POSTERIOR PROBABILITY x 
positive: •fistulae 
fever 
IgA 
lgM 
·IgG 
negative: bloody stools 
haematocrit 
disease restricted to ileum 
x: P < 0.05; ·:P < 0.01 
statistical significance. 
(D) Crohn's disease ver·sus healthy subjects. Patients with Crohn's dis-
ease had more positive reactions with all strains (P < 0.0001) and, con-
sequently, higher a posteriori probabilities than healthy subjects. 
(E) Ulcerative colitis versus healthy subjects. Patients with ulcerative 
colitis showed more positive agglutination reactions with strains C 18 
(P < 0.025) and Me 46 (P < 0.0025) than healthy subjects, resulting in 
higher a posteriori probabilities of Crohn's disease (P < 0.01). 
(F) Crohn's disease versus ulcerative colitis. Patients with Crohn's dis-
ease had more positive agglutination reactions with all strains than pat-
ients with ulcerative colitis (~1e 44 and C 18: P < 0.0001; Me 46 and Me 
47: p < 0.00025). 
(G) Crohn•s disease of the colon versus ulcerative colitis. Comparison 
of patients with ulcerative colitis and Crohn•s disease may result in 
37 
deceptive conclusions due to the heterogeneity of the Crohn group with 
respect to site of disease. Therefore, ulcerative colitis was also com-
pared with Crohn's disease of the colon.Similar results were obtained as 
under (F), the only relevant difference being a decrease of the signif-
icance of the correlation between Crohn's disease and agglutination with 
strain Me 47 from P < 0.00025 to P < 0.01, due to the low reactivity of 
strain Me 47 in colonic Crohn's disease. 
DISCUSSION 
In Crohn's disease no correlation. was found between antibodies to coccoid 
rods and any index of disease activity, age, duration of disease and bowel 
resection. On the other hand, antibodies were found more frequently when 
the disease was localized in the colon, when fistulae were present and 
when immunoglobulin levels were relatively high. 
Agglutination with strain Me 46 was less frequently positive in patients 
with bloody stools. The negative effect of bloody stools must be strong 
as it was seen despite the high frequency of agglutination with Me 46 in 
colonic Crohn's disease and the positive correlation between colonic dis-
ease and bloody stools. 
The data suggest that a limited number of features acts upon the produc-
tion of antibodies to the coccoid rods. We suppose that the presence of 
the anaerobic coccoid rods in the faecal flora is a necessary but not the 
only determinant for the production of antibodies to levels that allow 
their demonstration with agglutination reactions. 
The first contributory determinant probably is the high number of coccoid 
rods in the faecal flora, which, in patients with Crohn 1 S disease, is 
about fourty times higher than in healthy subjects. The negative effect 
of bloody stools on some agglutination reactions might be due to a de-
crease of the number of anaerobic bacteria. 
A second contributory determinant probably is colonic disease. In the 
colon, bacterial antigen concentration is certainly higher than elsewhere 
in the intestine and conditions for antibody production are optimal when 
an inflammatory process is localized there. The correlation between ag-
glutination reactions and fistulae may also be explained in this way, al-
though it may be supposed that certain strains cause both antibody pro-
duction and fistulae. 
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A third contributory determinant seems to be a high level of serum im-
munoglobulins. It is unlikely that antibodies to coccoid rods only are 
responsible for higher levels. Both immunoglobulin levels and titres 
of antibody to the coccoid rods are probably determined by the strength 
of the general humoral responsiveness. This response shows marked indi-
vidual variations in healthy subjects and in patients, as is evident from 
the wide range of immunoglobulin levels. This mechanism may be responsible 
for positive agglutination reactions in diseases with hyperimmunoglobul-
inaemia, like cirrhosis of liver, schistosomiasis, leprosy and ankylo-
sing spondylitis (see Chapter 3). 
Summarizing, it is concluded that for antibody production to the coccoid 
rods in patients with inflammatory bowel disease the high number of coc-
coid anaerobes probably is a necessary determinant. Contributory deter-
minants probably are colonic disease, fistulae and the strength of the 
humoral immune response. 
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chapter 
ANTIBODY NATURE AND BIOLOGICAL PROPERTIES OF AGGLUTININS AGAINST 
EUBACTERIUM AND PEPTOSTREPTOCOCCUS 
INTRODUCTION 
In Chapters 3 and 4 it has been shown that a high percentage of sera 
from patients with Crohn's disease agglutinate isolates belonging to 
Eubacterium and Peptostreptococc~. It was most likely that agglutina-
tion was due to immunoglobulins. Their physical-chemical properties and 
biological effects like activation of complement and opsonization were 
studied and the results are described in this chapter. 
MATERIALS AND METHODS 
Sera were obtained from patients with definite Crohn's disease (see Chap-
ter 4) and selected on positive agglutination reactions. Agglutination 
reactions were performed as described in Chapter 3. Agglutinating titres 
were determined with sera diluted with 0.9% saline. Sera were absorbed 
by' incubating 0.5 ml under continuous rotation for 1 h at 20°C with the 
sedimented bacteria of 1.5 ml of the agglutination suspension (Chapter 3). 
Immunoglobulin class was determined by applicati-on of the sera to a Se-
phadex G-200 column, according to Thompson and Stokes (1977). The efflu-
ents obtained after gel filtration were pooled as far as they belonged 
to the same protein peaks in the chromatogram and were concentrated to 
1 ml by selective membrane filtration (Ami con B 15, Ami con Corp., Lexing-
ton, USA). Immunoglobulin levels in the concentrated fractions were dete~ 
mined with radial immunodiffusion as described by Milford-Ward (1977) 
with commercially available plates and reference serum (Behringwerke AG, 
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~larburg, Federal Republic of Germany). 
The accuracy and precision of radial immunodiffusion was established 
with 12 determinations on different plates and occasions of the concen-
trations of lgA, IgG and lg~l in the reference serum batch. 
From Table 1 it is seen that coefficients of variation were 4.8, 3.2 
Table 1. Immunoglobulin levels of reference serum 
IMMUNOGLOBULIN 
(mg/100 ml serum) 
IgA lgM !gG 
reference va 1 ue*: 242 108 1260 
number of determination 
1 244 88 1195 
2 267 86 1303 
3 244 99 1278 
4 245 69 1210 
5 244 92 1181 
6 234 79 1198 
7 220 93 1238 
8 250 106 1216 
9 255 88 1231 
10 233 90 1254 
11 244 96 1169 
12 240 81 1216 
mean value: 243 89 1224 
standard deviation: 11.7 9.7 39.3 
coefficient of variation(%): 4.8 10.9 3.2 
deviation from reference value(%):+0.4 -21.4 -2.9 
'") Serum batch no. 1001 obtained from and reference 
values given by Behringwerke AG, Marburg, Federal 
Republic of Germany. 
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and 10.9%, respectively and the prec1s1on therefore is within acceptable 
limits. Accuracy was good for IgA (deviation 0.4%) and IgG (deviation 
2.9%). lgM was found to be about 20% lower than the value given by 
Behringwerke. 
Table 2 records the results of immunoglobulin determinations with radial 
Table 2. Immunoglobulin levels of IgM and IgG 
fra~tions of sera from patients with Crohn's disease 
CODE NO. IG LEVELS OF IGM 
OF SERUM FRACTIONS* 
2593 
2627 
2628 
2629 
2660 
2702 
2728 
2752 
2740 
21 
27 
30 
34 
29 
32 
32 
10 
4 
68 
68 
65 
61 
76 
48 
76 
34 
58 
!gG 
2 
2 
3 
3 
3 
2 
3 
10 
1 
IG LEVELS OF IGG 
FRACTIONS* 
45 
42 
29 
44 
39 
21 
51 
34 
18 
2 
7 
0 
5 
11 
1 
11 
0 
2 
1..9§. 
66 
78 
55 
78 
57 
45 
63 
37 
56 
*) Percentages of whole-serum levels. 
immunodiffusion in the pooled and concentrated effluents after applica-
tion of sera from 9 patients with Crohn's disease to Sephadex G-200 col-
umns. The "lgM fraction" predominantly contained lgM and only slight 
amounts of IgG and the 11 lgG fraction 11 vice versa. Both fractions, how-
ever, contained IgA. 
Complement fixation by agglutinin-antigen complexes was tested by 
incubation during 16 h at 4° C with guinea-pig complement. 
Residual complement was determined by the degree of lysis of the haemo-
lytic system. Preserved guinea-pig serum (Wellcome, Beckenham, England) 
was used as a source of complement. Sheep red cells in A]sever 1 s solut-
ion were obtained from the Rijks Instituut voor de Volksgezondheid, Silt-
hoven, washed and diluted in complement fixation test diluent (Oxoid Ltd., 
London, England). Rabbit haemolytic serum was obtained from Well come. 
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Verification. All four sensitized strains incubated with anti-human im-
munoglobulin antibodies (RAHu/Fc, Nordic, Tilburg) bound complement and 
the anticomplementary titres were much higher than of controls in which 
unsensitized bacteria were incubated with anti-human immunoglobulin anti-
bodies only (Table 7). It is clear, therefore, that complement fixation 
by antigen-antibody complexes was demonstrated with this assay. 
Control experiments in saline showed that three of the bacterial strains 
fixed camp l ement. The method of Fine et al. ( 1972) was used to see 
whether complement was activated by the alternative pathway. This method 
depends upon the fact that, whereas the classical pathway requires both 
calcium and magnesium, the alternative pathway requires only magnesium. 
Calcium was chelated with the magnesium salt of ethyleneglycoltetraacetic 
acid (Mg EGTA) as described by Bryan (1974) and Fine (1977). After incuba-
tion with chelated fresh human control serum, bacteria were sedimented 
at 10,000 g. The supernatant was withdrawn and 0.1 ml of 100 mM cac1 2 
per ml of serum was added before addition of the haemolytic system. 
Tests were performed with serum from two healthy subjects. 
Verification. Treatment of fresh human control serum with Mg EGTA com-
pletely inhibited lysis of the haemolytic system, but haemolysis occur-
red after saturation with calcium, indicating that the classical pathway 
had indeed been inhibited by Mg EGTA. 
Phagocytosis. Neutrophils were isolated according to Boyum (1968) with 
modifications by Steffelaar et aZ. (1976). Blood was obtained from heal-
thy laboratory volunteers and heparinized with 10 IE/ml of Thromboliquine 
(Organon, Oss). After harvesting, cells were suspended in concentrations 
of 2 x 106 cells/ml in "Hijmans" fluid (see Steffelaar et aZ., 1976). 
To 0.2 ml of this suspension, 0.2 ml "Hijmans" fluid and 0.2 ml of bac-
terial suspension (see below) were added and the mixture was incubated 
for 30 min at 370C under continuous rotation. The tubes were centrifuged 
for 10 min at 90 g, the pellet was resuspended in saline and slides were 
prepared. After Gram staining, 200 cells were counted per slide and the 
percentage of cells containing bacteria in vacuoles was calculated from 
duplicate counts. All tests were performed in duplicate. The coefficient 
of variation was 13%. 
Preparation of sensitized bacteria. To 0.125 ml of a washed bacterial 
suspension, 0.25 ml of antibody-containing samples was added. After in-
cubation under continuous rotation for 1 h at 2ooc and subsequent 
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sedimentation, the bacteria were washed and resuspended in 0.9% saline. 
Whole Crohn's serum, specifically absorbed serum and the lgG and !gM 
fractions obtained after gel filtration were used as sources of anti-
bodies in 4 dilutions (1/1, 1/2, 1/4 and 1/8) and heated for 30 min at 
56°C to inactivate complement. IgG and lgM concentrations were expres-
sed as percentage of Ig in undiluted serum. 
RESULTS 
Agglutination titres. In Table 3 results are presented of agglutination 
Table 3. Titres of serum agglutinins to coccoid 
rods in patients with Crohn's disease 
CODE NO. AGGLUTINATION'" TITRE$ TO STRAINS: 
OF SERUI~ ME 44 c 18 ME 46 ME 47 
2593 3 2 3 2 4 4 2 2 
2627 3 3 3 3 1 8 8 4 
2628 3 3 3 0 8 16 32 
2629 3 3 3 3 4 4 4 2 
2702 3 3 3 3 1 1 2 4 
2728 2 3 3 1 1 4 2 1 
2740 3 3 3 1 8 16 8 1 
2752 1 3 3 2 2 2 8 4 
'") Results for strains Me 44, c 18, ~le 46 and Me 47 
according to strength of agglutination (0, 1, 2 or 3). 
reactions with diluted sera from 8 patients with Crohn's disease. This 
table shows that the titres were usually low. 
Absorption of agglutinins. In Table 4 results are given of agglutination 
reactions before and after absorption of two sera from patients with 
Crohn's disease with each of the 4 strains. From this table it is 
evident that agglutinins were absorbed specifically. 
Immunoglobulin class of agglutinins. The agglutination reactions of sera 
from 13 patients with Crohn's disease are given in Table 5. From this 
table it is seen that the agglutinins in the lg_M and lgG fractions were 
responsible for agglutination by whole serum. The data are grouped 
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Table 4. Absorption of agglutinins from 2 Grahn 
sera by coccoid rods 
whole serum 
after incubation with 
strain: 
Me 44 
c 18 
Me 46 
Me 47 
AGGLUTINATION'" 
Crohn serum no. 
2701 2719 
3 3 3 2 
0 3 3 2 
2 0 3 2 
3 3 0 2 
3 3 3 0 
3 3 3 2 
0 3 3 2 
3 0 3 2 
3 3 0 2 
3 3 3 0 
'") Results for strains Me 44, C 18, Me 46 and ~le 
47 according to strength of agglutination. 
Table 5. Agglutination of coccoid rods by Crolm 
sera~ IgM and IgG fractions 
WHOLE SERUM IGM FRACTION IGG FRACTION 
code no. aggl uti nation'" agglutinatio~agglutination'" 
2593 3 2 3 2 0 0 0 1 3 3 3 0 
2627 3 3 3 3 2 1 0 3 2 3 3 0 
2628 3 3 3 0 3 0 3 0 3 3 3 0 
2629 3 3 3 3 2 3 3 3 3 3 3 0 
2657 3 0 3 0 0 0 0 0 3 0 3 0 
2660 3 3 3 0 0 1 0 0 2 0 3 0 
2669 3 1 2 1 0 1 0 1 3 3 0 0 
2677 3 3 0 2 2 0 0 0 2 2 0 3 
2702 3 3 3 3 0 0 0 0 2 0 0 1 
2728 2 3 3 1 0 2 0 0 0 3 2 0 
2752 1 3 3 2 0 0 0 2 0 3 2 2 
2831 2 3 3 1 0 3 2 1 2 3 0 0 
2832 3 3 3 1 3 3 0 2 3 3 3 1 
'") Results of strains Me 44, C 18, Me 46 and Me 47 
according to strength of agglutination. 
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in Table 6, which shows that agglutinins to Me 44 were usually present 
in the !gG fraction and less frequently in the IgM fraction. Agglutin-
ins to C 18 were found in both fractions, whereas those to ~le 46 were 
mostly lgG and to r~e 47 IgM. 
TohZe 6. AggZutinins in IgM o:nd IgG fraetions of 
sera from 13 patients with Grahn's disease 
STRAIN NO.OF AGGLUTINATING NO. OF AGGLUTINATING 
SERA FRACTIONS 
!gM IgG I~M and !gG 
Me 44 13 0 6 5 
c 18 12 1 4 6 
~le 46 12 1 7 2 
Me 47 10 5 2 2 
Complement activation. Unsensitized bacteria. Strain Me 44 showed no 
anticomplementary activity at all. The median titre was 8 for C 18 and 
32 for Me 46 and Me 47 (Table 7). Complement activation by the alter-
native pathway of the bacterial strains was tested by incubation with 
fresh, Mg EGTA chelated control serum. No lysis of the haemolytic sys-
tem was observed after saturation with calcium of the supernatant chela-
ted sera incubated with strains C 18, ~le 46 and Me 47. In contrast, 
chelated serum incubated with Me 44, as expected, induced lysis. From 
the results it is concluded that strain Me 44 does not activate comple-
ment, whereas C 18, Me 46 and Me 47 activate complement by the alterna-
tive pathway. Some classical pathway activation by the latter strains 
is not excluded by this experiment. 
Sensitized bacteria. As can also been seen from Table 7, sensitized bac-
teria had anticomplementary titres equal to or lower than those found 
with unsensitized bacteria. Whereas higher titres would have indicated 
complement fixation by specific antibodies, equal or lower titres could 
also be caused by the bacteria themthelves. Therefore, the amount of 
antibody was varied by incubation of bacteria with serum dilutions rang-
ing from 1/1 to 1/1024. Table 7 shows that anticomplementary activity 
of antibody-coated C 18 diminished when higher dilutions of serum were 
applied, indicating that it was (partly) caused by antibodies. The anti-
complementary activity found with Me 46 and Me 47 did not diminish at 
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Table 7. Anticomplementary activity of coccoid rods 
PRETREATMENT1 
OF BACTERIA: 
Saline 
test 1 
2 
3 
4 
Crohn serum 
2783 
2735 
2831 
2832 
2835 
1/1 
1/2 - 1/4 
1/8 - 1!1024 
2831 
+ anti-Ig 
2832 
+ anti-Ig 
Anti-Ig 
ANTICOMPLEMENTARY TITRE2 
WITH STRAIN: 
~,le 44 C 18 Me 46 Me 47 
0 8 64 64 
0 4 32 32 
0 8 32 32 
0 4 32 32 
0 4 
8 32 
0 8 8 16 
0 8 4 8 
0 32 16 32 
0 8 16 32 
0 4 16 32 
64 64 64 64 
64 64 64 64 
0 8 32 16 
1) Pretreatment during 1 hat 20oc. 
2) -: not tested 
higher serum dilutions and it is concluded that antibodies to these 
strains, like those to 11e 44, lacked complement fixing properties. 
Phagocytosis. Results of phagocytosis in control experiments with bac-
teria in o.g% saline are given in Table 8, from which it is seen that 
phagocytosis of strains Me 44 and C 18 was slight in contrast to strains 
Me 46 and Me 47 which were taken up by 45-61% of the neutrophils. 
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Table 8. Phagocytosis of coccoid rods by neutrophils 
STRAIN1 % OF NEUTROPHIL$ CONTAINING COCCOID RODS2 
Me 44 
c 18 
Me 46 
Me 47 
19 (14 - 28) 
10 ( 5 - 19) 
61 (54 - 63) 
45 (24 - 48) 
1) Coccoid rods suspended in 0.9% saline. 
2) Median values of 4 determinations; range in parentheses. 
Sensitized bacteria. Strain Me 44. From Fig. 1 it is evident that mark-
ed phagocytosis of Me 44, related to the amount of antibody, was induced 
by whole serum and the lgG fraction. After absorption of the serum with 
Me 44, phagocytosis was negligible. Fig. 2 shows that the lgG fraction 
and whole serum were active, whereas the Ig~1 fraction and absorbed serum 
showed no opsonic effect. From these results it is concluded that lgG 
agglutinins to Me 44 had opsonic properties, whereas no such effects 
could be demonstrated of lgM agglutinins. 
NEUTROPHIL$ CONTAINING BACTERIA(%) 
100 
50 
0 
0 0.5 1.0 
!G/!G UNDILUTED SERUM 
Fig.l. Phagocytosis of Me 44 after 
incubation with serum ( .._.; ~ the 
IgG fraction ( --•) and absorbed 
serum (o--o). *Control in 0.9% 
saline. Grahn serum no. 2831~ ag-
glutinins only of IgG class 
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NEUTROPHILSCONTAINING BACTERIA(%) 
100 
50 
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Fig.2. Phagocytosis of Me 44 after 
incubation with serum (---.}~ the 
IgG fraction ( --•!, the IgM fraa-
tion ( •···•} a:nd absorbed serum 
(o--o}. *Control in 0.9% saline. 
Crohn serum no. 2832~ agglutinins 
of IgG and IgM c Zass 
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Fig.3. Phagocytosis of C 18 after 
inr::Ubation with serum ( .......... ; ;:J the 
IgG fraction ( e--.e), the IgM frac-
tion ( •-.. ) a:nd absorbed serum 
(e--o). *Control in 0.9% saline. 
Crohn serum no. 2831:> agglutinins 
of IgG and IgM class 
Strain C 18. From Fig. 3 it is seen that opsonization of C 18 by specific 
antibodies was similar to that of Me 44. 
Strain Me 46. Fig. 4 shows that phagocytosis of Me 46, preincubated with 
whole serum, the lgM fraction and absorbed serum was lower than in the 
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Fig.4. Phagocytosis of Me 46 after 
incubation with serum (---.):> the 
IgM fraction ( .. -·•! and cibsorbed 
serum (o-o). *Control in 0.9% 
saline. Grahn serum no. 2831:> ag-
glutinins only of IgM class 
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Fig.5. Phagocytosis of Me 46 after 
incubation with serum (e--e);:J the 
IgG fraction (•--•! and cibsorbed 
serum (o--o). *Control in 0.9% 
saline. Crohn serum no. 28323 ag-
glutinins only of IgG class 
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Fig.6. Phagocytosis of Me 47 after 
incubation with serum (---.)~ the 
IgM fra~tion ( ..... e) and absorbed 
seY'V.m (o--o}. *Control, in 0.9% 
saline . Crohn serum no. 2831~ 
agglutinins onZy of IgM class 
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Fig.?. Phagocytosis of Me 47 after 
incubation with serum (e--e) 3 the 
IgG fra~tion ( o--•), the IgM frac-
tion ( •·--•) and absorbed serum 
{c-o). *Control in 0.9% saline. 
Crohn serum no. 2832~ agglutinins 
of IgG and IgM ~lass 
Table 9. Summary of results on complement fixation and phagocytosis 
STRAIN 
Me 44 c 18 Me 46 Me 47 
anticomplementary activity 0 + ++ ++ 
activation of complement by 
alternative pathway 0 + + + 
fixation of complement by 
specific antibodies 0 + 0 0 
phagocytosis 
unsensitized bacteria ± ± ++ ++ 
bacteria sensitized with: 
positive Crohn sera ++ ++ 0 ++ 
negative Crohn sera n.t. n.t. 0 n.t. 
in the presence of complement n.t. n. t. +++ n.t. 
n. t. : not tested 
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control. Similar results were obtained with serum with only IgG agglut-
inins and the IgG fraction (Fig. 5). This differs markedly from the re-
sults obtained with the other strains. The inhibitory effect of whole 
serum and absorbed serum was confirmed with three other positive Crohn 
sera. Sera from three Crohn's patients without Me 46 agglutinins and 
serum from a healthy subject also inhibited phagocytosis. It is evident 
that results with Me 46 differ in two respects from those with Me 44 and 
c 18: 
(1) the IgG agglutinins do not promote phagocytosis; 
(2) phagocytosis is inhibited by serum, IgG and IgM fractions and 
also by absorbed serum. 
Obviously, inhibition of phagocytosis is not mediated by the agglutinins 
but by another, unknown factor present in serum and absorbed serum. So 
far, results were obtained with serum samples in which complement had 
been inactivated. To see whether complement could promote phagocytosis 
despite the presence of inhibitory serum or non-opsonizing antibody, 
phagocytosis was investigated with bacteria preincubated with fresh 
serum. In these cases, 90-100% of neutrophils contained bacteria and 
phagocytosis was therefore higher than with the controls in saline. 
Strain Me 4?. From Fig. 6 and 7 it is seen that IgG agglutinins to Me 
47, like those to Me 44 and C 18, were opsonins. Absorbed serum, as in 
the case with Me 46, also inhibited phagocytosis but the effect was not 
strong enough to counteract the opsonic effect of IgG agglutinins. 
Conclusions. IgG agglutinins to Me 44, C 18 and Me 47 induced phago-
cytosis, despite the presence of specific IgM antibodies or (inhibiting) 
serum. IgG antibodies to Me 46 from patients with Crohn's disease, on 
the other hand, lacked opsonizing properties. 
Results of complement fixation and phagocytosis are summarized in Table 
9. 
DISCUSSION 
Bacteria. Unexpectedly, it was found that strains C 18, Me 46 and Me 47 
activate complement. As this occurred in the absence of antibodies, it 
was most likely to proceed by the alternative pathway and this was con-
firmed experimentally. Activation of complement usually results in the 
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elimination of invading microorganisms like Haemophilus influenzae 
(Quinn et al., 1977), group B Streptococcus (Shigeoka et al., 1978), 
Neisseria gonorrhoeae(Ingwer et al., 1978) and Pseudomonas aeruginosa 
(Peterson et al., 1978), but has also been supposed to initiate inflam-
matory reactions. Propionibacterium ac~s probably causes acne vulgaris 
in this way (Webster et aZ., 1978; Dahl et al., 1979). 
Underphysiological conditions, little if any complement is present in the 
external secretions of the gastrointestinal tract but once the mucosa 
is inflamed, complement could be brought into play, giving rise to sub-
mucosal reactions (Thompson, 1979). Feinstein et al. (1976) found abnor-
malities in the alternative pathway activation in Crohn's patients which 
could not be demonstrated during remissions (Lake et aZ., 1979). 
Bacteria of the resident intestinal flora are obviously not eliminated 
by complement activation under these circumstances. Complement cleavage 
and its effects (histamine release, kininlike activity, chemotactic ac-
tivity, lysosomal enzyme release) may be expected to occur continuously 
and to contribute to perpetuation of the inflammatory process. 
Antibodies. The occurrence of the agglutinins in the IgG and IgM fraction, 
the specific binding to antigen and the opsonic effect are compatible 
with their immunoglobulin nature. 
Antibodies to Peptostreptoaoaaus productus strain C 18, fixed complement 
and had a marked opsonic effect. This suggests that a normal immune 
defence mechanism against infection by Peptostreptococcus produotus is 
likely to occur when the organism enters the tissues. 
The antibodies to the Eubacterium contortwn strains ~1e 44 and Me 47 had 
also an opsonic effect, but in contrast to antibodies to Peptostrepto-
coeeus productus lacked complement fixing properties. 
Antibodies to the Eubacterium rectale strain Me 46, however, lacked both 
opsonizing and complement fixing properties. This may be important as 
the strain itself activated complement. Phagocytosis of strain Me 46 
could be induced by complement but complement also is consumed by the 
bacteria by the alternative pathway. It is impossible to predict the 
biological consequences of the interactions between strain Me 46, 
specific antibodies, complement and neutrophils in vivo in inflamed bowel 
in conditions of limited complement availability. Complement may act as 
the limiting factor for both phagocytosis of the bacteria and activation 
of complement by these bacteria. These phenomena may thus be competitive 
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and represent a state of unstable equilibrium. 
Both properties of strain Me 46, viz. activation of complement and re-
sistence to phagocytosis despite the presence of specific antibodies 
may thus be of pathogenetic importance for Crohn's disease. 
The absence of complement fixing and opsonizing properties of anti-Me 
46 antibodies in patients with Crohn's disease suggests that they belong 
to the lgG4 subclass. Specific IgG4 antibodies are rather unusual and 
only reported as auto-antibodies to clotting factors (Anderson & Terry, 
1968) and as antibodies to grass pollen (Van Der Giessen et aZ., 1976; 
Devey et al., 1976). The capacity to produce antibodies to one or an-
other lgG subclass to particular antigens is under genetic control (Nat-
vig & Kunkel, 1973) and shows marked geographic variations (Fudenberg 
et al., 1978). The production of antibodies of this "non-phagocytic" 
subclass to strain Me 46 in patients with Crohn's disease may thus be 
a reflection of a genetic predisposition. Other diseases exist in which 
associations with IgG subclasses or genetic markers on IgG have been 
found. Examples are typhoid, leprosy, auto-immune haemolytic anaemia, 
cystic fibrosis and atopic diseases (Van Der Giessen et aZ., 1976; 
Devey et al., 1976; Shakib et al., 1976; Shanfield, 1978). 
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chapter 
INTRODUCTION TO A LOGICAL INTERPRETATION OF DIAGNOSTIC LABORATORY TESTS 
The concepts of normal limits, sensitivity, specificity, a priori and 
a posteriori probability of disease have received some attention in 
recent medical literature (Price & Vlahcevic, 1971; Holland & White-
head, 1974; McNeil eta~., 1975; Wulff, 1976; Garry eta~., 1978; Burke, 
1978; Ransohoff & Feinstein, 1978; Diamond & Forrester, 1979) but are 
not familiar to many of those who interpret test results. The interpre-
tation of test results, however, largely depends on these concepts and 
their importance for clinical decisions, therefore, is discussed. 
An ideal test would always be positive in the presence of disease and 
negative in its absence and the interpretation of the test should be 
simple. Usually, however, tests yield quantitative results with overlap 
between diseased and non-diseased subjects. At least two different pro-
cedures can be followed to interpret individual test results. Results 
may be classified as normal or abnormal on the basis of a selected cut-
off point. Alternatively, the numerical value of the test result may be 
interpreted in terms of a posteriori probability of the disease concerned~ 
APPLICATION OF A CUTOFF POINT 
The problem is where to draw the line separating normal from abnormal 
values. In Fig. 1 several possible cutoff points are given and when 
point A was chosen, about 95% of non-diseased subjects would have 
normal results, compared to a third of diseased subjects. If all dis-
eased subjects should be detected, the line should be drawn at a lower 
value, say point B. As a consequence, more non-diseased subjects will 
have abnormal test results than at point A. If it is desired, on the 
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other hand, that abnormal test results certainly indicate the presence 
of disease, a higher value will be chosen (point C), but this results 
in a higher number of undetected diseased subjects than at points A or B. 
NUMBER N 
D 
TEST RESULT X 
Fig. 1. Frequency distribution of the results x of a hypothet-
ical test performed in patients (curve D) and non-diseased 
subjects (curve N). Points A~ B and C refer to several cutoff 
points separating normal from abnormal values 
Once a cutoff point is selected, sensitivity and specificity of the test 
can be calculated. Sensitivity is the percentage of abnormal tests in 
subjects who do have the disease. Specificity, on the other hand, is the 
percentage of normal test results in subjects without that particular 
disease. Sensitivity and specificity thus indicate the probability of a 
test result for classified subjects. The clinician, however, wishes to 
determine the probability of disease on the basis of the test result, 
i.e. the predictive value of a positive or negative test. The predictive 
value, or a posteriori probability of disease, not merely depends on 
sensitivity and specificity of the test, but is also largely influenced 
by the prevalence of the disease (a priori probability) in the popula-
tion tested. This is illustrated by the following (fictitious) example: 
A test is used of which the results may vary from 0 to 1. A cutoff point 
was chosen that resulted in a sensitivity of the test of 75% and a spec-
ificity of 94%. Consequences of application of thi·s test are illustrated 
when used in a population with a prevalence of disease of 50% and in a 
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population with a prevalence of 56 per 105 inhabitants'. 
A) Prevalence = 50%. When 1000 subjects are tested, 500 have the dis-
ease of which 0.75 x 500 = 375 will show a positive and 125 a negative 
test. Of the 500 non-diseased subjects, 500 x 0.94 = 470 will have a 
negative and 30 a positive test. The total number of positive results is 
375 + 30 = 405 of which 375 were obtained from diseased subjects. The 
probability of disease for a positive2 test thus is 375/405 = 0.93 (see 
Fig. 2). The total number of negative results is 125 + 470 = 595 of 
which 125 were derived from diseased subjects. Consequently, the probab-
ility of disease for a negative test2 is 125/595 = 0.21 (Fig. 2). From 
these data it is evident that a positive result strongly supports the 
presence of disease but a negative test does not exclude disease. The 
total number of misclassifications is 125 (negative results in diseased 
subjects) + 30 (positive results in non-diseased subjects) = 155 and the 
percentage of misclassifications of all tests is 155/1000 x100% = 15.5% 
(Fig. 3). 
B) Prevalence = 0.056%. In an analogous way as under (A) it can be cal-
culated that with the same test, but used in a population with lower 
prevalence, the probability of disease for a positive test is 0.007 and 
for a negative test 0.0001. The percentage of misclassifications is 6%. 
From the results it is concluded that in this population a positive test 
does not indicate disease. The interpretations of positive and negative 
tests are thus identical and consequently, the test should not be done 
in this population. 
')This is the prevalence of Crohn's disease in the City of Cardiff in 
1977 (Mayberry et aZ., in press). 
2 ) The results may also be obtained by application 
P(T+IO+) P(O) 
of Bayes' theorem: 
P(O+IT+) = 
P(T+IO+) P(O) + {1 - P(T-10-)} {1 - P(O)} 
P(O+IT-) = 1-
P(T-10-) {1- P(O)} + {1- P(T+IO+)} P(O) 
P(T-10-) {1 - P(O)} 
with: P(O+IT+) 
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P(O+IT-) 
P(O) 
P{T+IO+) 
P(T-10-) 
a posteriori probability of disease for a positive test 
a posteriori probability of disease for a negative test 
a priori probability of disease} expressed as numbers 
sensitivity of the test between o and 1 
specificity of the test 
In Fig. 2 the relationship between prevalence of disease and a postePioYi 
probabilities of disease for positive and negative tests are shown. From 
this figure it is seen that probabilities of disease increase at increas-
ing prevalence of disease but may theoretically vary from 0 to 1. In Fig. 
3 the percentage of misclassifications is given for all tests in this 
PROBABILITY OF DISEASE 
1.0 
0.5 
b 
0 
0 50 100 
PREVALENCE (%) 
Positive test result 
PROBABILITY Of DISEASE 
1.0 
0.5 
a 
"" 
50 
PREVALENCE 
Negative test result 
100 
(%) 
Fig. 2. A posteriori probabilities of disease for positive and negative 
test results in relation to the prevalence of disease. Points a and b 
correspond to the exampZes with prevalence of 50% (a) and 0.056% (b)~ 
respectively. Figure applies to a test with sensitivity of 75% and 
speeifieity of 94%. 
specificity 
MISCLASSIFICATIONS (%) 
- -100 l 
50 
0 50 100 
PREVALENCE (%) 
sens i ti vi ty 
Fig. 3. Misclassifications (%) for all test results in retation to the 
prevalence of disease. Points a and b correspond to the examples with 
prevalence of 50% (a) and 0.056% (b)~ respectively. Figure applies to 
a test with sensitivity of 75% and specificity of 94%. 
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example as a function of the prevalence of disease. From this figure it 
is seen that the chance of misclassification increases at increasing 
prevalence. For a test with a sensitivity higher than its specificity, 
the chance of misclassification undergoes changes in an opposite direc-
tion at increasing prevalence. 
Depending on the reasons for performing a test, the relevance of mis-
classification at negative and positive results in not the same. Statis-
tical methods are available to select an appropriate cutoff point depen-
ding on the relevance of false negative and false positive results and 
the prevalence of disease in the population tested (Metz et aZ., 1973). 
A major disadvantage of interpretation of test results on the basis of 
a cutoff point is that the test subsequently only has two possible out-
comes. For many tests, the numerical value of the result is much more 
relevant than the conclusion that the result is simply higher or lower 
than a chosen cutoff point. The way in which tests may be interpreted 
without application of a cutoff point is discussed in the next para-
graph. 
INTERPRETATION OF TESTS IN TEru~S OF PROBABILITIES OF DISEASE 
In Fig. 4 the frequency distribution is given of the numerical outcomes 
of the same hypothetical test as in Fig. 1. The probability that a sub-
ject with test result x belongs to either population, is proportional 
NUMB R N 
t 
x, TEST RESULT X 
Fig. 4. F~equency distribution of the same hypothetical test PesuZts as 
in Fig. 1. The number of subjects with test result x is indicated by 
fN for the non-diseased subjects and by fD for the diseased subjects 
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to the frequencies of that particular value x in the populations concer-
ned (fN and fo) and can thus be written as: 
with: 
fN 
P(D-J x) ----
fN + fo 
P(D+Jx) a posteriori probability of disease for test result x 
P(D-Jx) a posteriori probability of non-disease for test result x 
fo frequency of test result x in the diseased group D 
fN frequency of test result x in the non-diseased group N 
These a posteriori probabilities are based on prevalences (or a priori 
probabilities) of disease and non-disease proporti ona 1 to the sizes of the 
populations N and D. In Fig. 4 two x values are indicated, x1 and x2. If 
test result x1 is obtained, the probability of the individual tested 
having the disease decreases whereas with result xz this probability in-
creases, both compared to the a priori probability of disease. 
INFORMATION FROM TEST RESULTS 
Tests are performed to obtain information about diagnoses and this in-
formation depends on three parameters: sensitivity and specificity of 
the test and the prevalence of disease in the population tested (Metz 
et ar., 1973). The information can also be defined as a function of 
a priori and a posteriori probabilities and essentially is the differ-
ence between them. In Fig. 5 the relationship between information1 ob-
tained by a test2 and the prevalence of disease in the population tested 
is shown. From this figure it is seen that the information reaches 
maximum values at a prevalence of disease of about 50% (a priori prob-
ability= 0.5), thus in situations with maximal diagnostic uncertainty. 
The information decreases at lower and higher prevalences or, in other 
words, the more certainty on the diagnosis is available, the less in-
formation is to be expected from test results. 
1) Calculated according to Metz et ar. (1973). 
2) The same hypothetical test as used before with sensitivity of 75% and 
specificity of 94%. 
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INFORMATION 
0.5 
0 50 100 
PREVALENCE (%) 
Fig. 5. Info~ation obtained by the same hypothetical test as used in 
figures 2 and ~in relation to the prevalence of disease in the 
population tested 
INTERPRETATION OF MORE THAN ONE TEST RESULT 
Sometimes, several diagnostic tests are available for a single disease 
and for the interpretation, the results should be combined. This may be 
accomplished by discriminant analysis with the following additional ad-
vantages: 
- there is no need to select a cutoff point for interpretation of the 
test result 
- test results are weighed for diagnostic relevance 
For test results with a normal distribution, linear discriminant analysis 
and for test results with discontinuous distributions, logistic discrim-
inant analysis may be used. In Chapter 7, application of logistic dis-
criminant analysis is described to interpret the results of the four 
agglutination reactions. 
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chapter 
ANTIBODIES TO EUBACTERIUM AND PEPTOSTREPTOCOCCUS AND THE ESTB~TED 
PROBABILITY OF CROHN 'S DISEASE* 
INTRODUCTION 
There is great variation in the duration of symptoms before the diag-
nosis of Crohn's disease (CD) is established, the average delay being 
3 to 4 years (Dyer & Dawson, 1970; Brandes & Eulenburg, 1976; Mekhjian 
et al., 1979). The diagnosis can be made only after thorough evaluation 
has excluded other causes of ileal or colonic disease. Unfortunately, 
there are up to now no laboratory tests to confirm the diagnosis. As 
has been described in previous chapters, antibodies to Eubacterium and 
Peptostreptoeoccus strains are found in a considerable percentage of 
sera of patients with CO. The antibody titres change only slightly or 
not at all during the disease. In healthy subjects and many other dis-
eases these antibodies are found less frequently. 
Apart from other implications of these findings, it is evident that the 
antibodies can serve diagnostic purposes. Four strains of the coccoid 
anaerobes seemed appropriate for discrimination between CD and non-CO. 
With each strain, agglutination can be negative (0) or positive, scored 
as 1, 2 or 3 according to strength. Because four strains are used as a 
set, 256 test results are possible. 
In this chapter, discriminant analysis is applied to the results of 
agglutination with the four strains. 
*) This chapter is based on a paper by Van De Merwe and Schmitz, sub-
mitted for publication. 
64 
~1ATERIALS AND METHODS 
Agglutination reactions. See Chapter 3. 
Patients and controls. Between October 1, 1975, and February 1, 1978, 
114 patients with CD and 95 healthy subjects were studied. Patients with 
CD, healthy subjects and sera were similar to those described in Chap-
ter 4. The agglutination reactions of patients and controls are given in 
Appendix II (p. 100). 
Statistical methods. Logistic discriminant analysis (Anderson, 1972) 
was used for discrimination between patients with CD and healthy sub-
jects (HS). Details of the method are presented in Appendix II. 
Allocation rules and interpretation. After calculation of the estimated 
a posteriori probability of CD, P(CD!x), several allocation rules may be 
used. It could be stated, for instance, that a subject with agglutina-
tion reactions x is classified as: 
-non-CO if 0 ~ P(CD!x) < 0.5 
- CD if 0.5 ~ P(CD!x) ~ 1 (1) 
When we classify as 11 CO" only when the a posteriori probability exceeds 
a certain value, say 0.8, and classify as "non-CD 11 when the probability 
is below another value, say 0.2, we have an allocation rule with are-
gion of doubt. Thus: 
-non-CO if 0 ~ P(CD!x) ~ 0.2 
- no decision (doubt) if 0.2 < P(CD!x) < 0.8 
- CO if 0.8 ~ P(CD!x) ~ 1 (2) 
On the basis of the results of the analysis (see Results), we divided 
the possible outcomes of a posteriori probabilities in four classes 
with the following interpretation: 
- no support for CD if 0 ~ P(CDix) < 0.8 
- suspected CD if 0.8 ~ P(CDix) < 0.95 
- probable CD if 0.95 ~ P(CDix) < 0.99 
- definite CD if 0.99 ~ P(CD!x) ~ 1 (3) 
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RESULTS 
The calculated a posteriori probabilities for the patients and controls 
are given in Table 1. When allocation rule (1) is used, classifications 
are obtained as summarized in Table 2. If allocation rule (2) were used, 
a classification is obtained as given in Table 3. From this table it is 
Table 1. Frequency distribution of posterior probabilities P(CD]x! of CD 
at prior probability of 0.5 in patients with CD and healthy subjects 
P(CD]x) CROHN'S DISEASE HEALTHY SUBJECTS 
0 - <0.10 0 0 
0.10 - <0.20 21 75 
0.20 - <0.30 3 4 
0.30 - <0.40 1 8 
0.40 - <0.50 3 2 
0.50 - <0.60 2 0 
0.60 - <0.70 4 2 
0.70 - <0.80 5 3 
0.80 - <0.90 11 1 
0.90 - <0.95 7 0 
0.95 - <0.99 9 0 
0.99 - 1 48 0 
Total 114 95 
Table 2. Classification matrix for allocation rule (1) 
POPULATION OF ORIGIN 
CD HS 
CD 86 6 
POPULATION OF ALLOCATION 
HS 28 89 
Total 114 95 
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Table 3. Classification matrix for allocation rule (2) 
POPULATION OF ORIGIN 
CD HS 
CD 75 1 
POPULATION OF ALLOCATION doubt 18 19 
HS 21 75 
Total 114 95 
evident that about 20% of the elements in both samples are not clas-
sified. With the use of the allocation rule (3) a posteriori probabil-
ities are obviously interpreted more realistically (Table 4). In this 
situation, 42% of the patients with CD are classified as "definite CD", 
8% as 11 probable CD 11 , 16% as 11 SUspected CD" and 34% as 11 nO support for 
CD". Of the healthy subjects, 99% are classified in this latter category, 
whereas only 1% is classified as 11 Suspected CD" and none as 11 probable 11 
or "definite C0 11 • 
Table 4. Frequency distribution of a posteriori probabilities P(CDixJ 
in four classes for allocation rule (3) in patients with CD and heal-
thy subjects (HS! 
P(CDix) INTERPRETATION NUMBER (%) OF CD NUMBER (%) OF HS 
0 - <0.80 no support for-CO 39 (34) 94 (99) 
0.80 - <0.95 suspected CD 18 ( 16) 1 (1) 
0.95 - <0.99 probable CD 9 (8) 0 (0) 
0.99 - 1 definite CD 48 (42) 0 (0) 
Total 114 (100) 95 (100) 
Calculation of a 2osteriori probabilities at a p_riori erobabilit;[ # 0.5. 
All estimations of probabilities of CD and the corresponding interpreta-
tions in this chapter have been based on a priori probabilities of 0.5. 
For applications at other a priori probabilities for all individuals, 
the formula (see Appendix II) as well as the interpretations of the 
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a posteriori probabilities have to be adjusted. For situations with 
considerable individual variations of a priori probabilities, the for-
mula cannot be adjusted individually because a reliable interpretation 
of the a posteriori probabilities is only possible on the basis of an 
evaluation of the results. With the present material, this is not pos-
sible. 
DISCUSSION 
With the system described, 50% of patients with known CD could be recog-
nized with only the agglutination reactions as 11 definite 11 or 11 probable 
CD". None of the healthy subjects were classified in these categories. 
Moreover, 16% of the patients with CD were classified as 11 SUspected CD 11 
compared to only 1% of healthy subjects. About one-third of the patients 
with CD were classified as "no support for CD" compared to 99% of heal-
thy subjects. From these results we conclude that application of the ag-
glutination reactions in combination with the interpretation given, 
yields an improvement in discrimination of individuals into groups of 
patients with CD and healthy subjects. If this system is used for diag-
nostic purposes, it should discriminate between 11 CD 11 and 11 non-CD 11 • The 
extrapolation from the group "healthy subjects" to "non-CD" is only al-
lowed when there are no relevant differences in frequencies and combi-
nations of agglutination reactions between these groups. In Chapter 3 
it is shown that this is true for a large number of 11 Control diseases 11 , 
but in a few diseases like cirrhosis of liver and coeliac disease, the 
results have to be interpreted otherwise. 
An objection is that the test is evaluated in the same samples as those 
with which the coefficients of the discriminant function were estimated. 
This is partly overcome by the verification as described in Appendix II 
(p. 98), but, ideally, the clinical value of a diagnostic test should 
be evaluated with samples of the patient population and a similar popu-
lation that only differs by the absence of the particular disease. The 
classification of patients as 11 CD 11 or 11 nOn-CD 11 , however, requires long-
term studies (4 years or more) and even then it is doubtful whether all 
subjects could be classified. 
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chapter 
GENER4L DISCUSSION 
In patients with Crohn's disease, conventional bacteriological and viro-
logical investigations have not revealed specific causative agents, but 
the number of investigations was small and the methods were rather 
conventional. Moreover, epidemiological data are not suggestive for 
an infectious nature of Crohn 1 s disease, but this is not a conditio 
sine qua non (ef. tetanus and actinomycosis). 
Like many other idiopathic diseases, Grahn's disease has been the sub-
ject of immunological studies. Reports in which deficient cellular im-
munity was found, have not appeared to be tenable as minor changes of 
cellular immunologic phenomena are probably secondary to active disease. 
More recently, immune complexes were found in 50% of patients with 
Grahn's disease, but the complexes demonstrated probably were heat-
aggregated immunoglobulins (Soltis et aZ., 1979a; 1979b). 
A wide variety of antibodies to bacteria, viruses and dietary proteins 
have been demonstrated, none of which appears likely to be of primary 
importance. 
So far, data don't support the hypothesis that Grahn's disease is caus-
ed by infectious agents or primary immunologic dysfunction. 
Concept of disease 
We have to consider the possibility that Grahn's disease will only 
become manifest after fulfilment of several conditions (McConnell, 1972; 
Ward, 1977). Even a typical infectious disease like tuberculosis is de-
termined by other factors than only the causative agent. Sequelae of in-
fection may vary from subclinical events to serious, sometimes lethal 
disease. In this multi conditional approach of disease, MYeobaeterium 
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tubercuZosis is not said to be the~ of tuberculosis, but a neces-
sary determinant. The clinical picture further depends on other neces-
sary or contributory determinants, some of which are genetically deter-
mined (Harvald & Hauge, 1965). 
Implications for Crohn 1 S disease 
The following data have to be considered when aetiological factors of 
Crohn 1 s disease are discussed: 
a) a genetic predisposition for Crohn's disease is likely (Kirsner, 
1973; Lewkonia, 1973), but genetic markers have not been found; 
b) Crohn's disease probably is a multiconditional disease; McConnell 
(1972) stated: "the environmental factor causing Crohn's disease is 
affecting large sections of the population, but only those with a 
genetic susceptibility develop the disease". 
c) patients with Crohn's disease have an abnormal faecal flora of 
probably permanent character; numbers of gram-negative anaerobes and 
of anaerobic, gram-positive coccoid rods are much higher than in 
healthy subjects (Wensinck, 1975; 1976). 
d) complement activation by the alternative pathway probably occurs in 
patients with Crohn's disease (Lake et al., 1979); 
e) Crohn's disease is a granulomatous disease; granuloma development 
is considered to represent a second line of defense, particularly 
when the evoking agent persists, has a particulate form and when 
antigen-antibody complexes are formed in antibody excess (Spector & 
Heeson, 1969; Spector, 1969; Adams, 1976) 
The following points, based on results in this thesis should be added: 
f) several bacteria of the resident faecal flora (C 18, Me 46 and Me 47) 
activate complement by the alternative pathway, obviously without 
their subsequent elimination (Chapter 5). 
g) if condition (c) is fulfilled, intestinal damage results in the pro-
duction of antibodies to the coccoid rods (Chapter 4). 
h) specific lgG antibodies fail to promote phagocytosis of strain Me 
46 in patients with Crohn's disease: these antibodies probably 
belong to a genetically determined subclass of lgG (Chapter 5). 
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On the basis of these data the following hypothesis is proposed and 
illustrated with strain f4e 46. The genetic predisposition of Grahn's 
disease consists of: 
(l) the presence of strain Me 46 in the resident faecal flora; 
(2) the property to produce, if other conditions are fulfilled, anti-Me 46 
non-opsonizing antibodies. 
Crohn's disease will only develop if some intestinal injury (ulcerative 
colitis, diverticulitis, enteritis caused by Yersinia~ Salmonella~ cam-
pylobaeter~ clostridial toxins ?) occurs but fails to induce opsonizing 
anti-Me 46 antibodies. The subsequent resistance to phagocytosis enhances 
the virulence of Me 46, mediated by activation of complement by the al-
ternative pathway which unfortunately cannot result in elimination of 
Me 46 from the resident intestinal flora. This activation of complement 
liberates major mediators of inflammation and results in intestinal 
damage. This secondary damage closes the circle. Particulate antigen-
antibody complexes persist and evoke a granulomatous inflammatory res-
ponse. a second line of defence. 
If only the first predisposition is present, intestinal damage will 
result in the production of anti-Me 46 antibodies of another (opsonizing) 
IgG subclass and the inflammation will subside. 
It should be noted here that agglutinating antibodies to Me 46 do not 
occur in all patients with Grahn's disease. Non-agglutinating antibodies 
may exist, however, but the occurrence of other strains and antibodies 
with similar biological effects in Grahn's disease is not excluded. 
In this hypothesis, Grahn's disease could be treated by the induction 
of antibodies to Me 46 of another IgG subclass, with complement fixing 
and opsonizing properties. Competition of these biologically active 
antibodies with inactive antibodies would restore the (unstable) equi-
librium that was present before Grahn's disease developed. 
72 
REFERENCES 
Adams, D.O. (1976) The granulomatous inflammatory response. A review. 
Am. J. Path. 84, 164-191 
Harvald, B. & M. Hauge (1965) Hereditary factors elucidated by twin 
studies. In: Genetics and the epidemiology of chronic disease. U.S. 
Public Health Service Publ., No. 1163, pp. 61-76 
Kirsner, J.B. (1973) Genetic aspects of inflammatory bowel disease. In: 
Genetics of gastrointestinal, disorde!'s. CUnies in gastroenteroZoey 8_, 
557-575 
Lake, A.~1., A.E. Stitzel, J.R. Urmson, W.A. Walker & R.E. Spitzer (l979) 
Complement alterations in inflammatory bowel disease. Gastroentex>oZ-cgy 
?6, 1374-1379 
Lewkonia, R.~1. (1973) Inherited immunological abnormality and the gut. 
In: Genetics of gastrointestinal disorders. Clinics in gastroenterology 
2, 645-660 
McConnell, R.B. (1972) Genetics of Crohn's disease. In: Crohn's disease. 
Clinics in gastroenterology 1~ 321-334 
Soltis, R.D., D. Hasz, r~.J. t1orris & !.D. Wilson (1979a) The effect of 
heat inactivation of serum on aggregation of immunoglobulins. ImmunoZogy 
$6, 37-45 
Soltis, R.D., D. Hasz, M.J. Morris & I.D. Wilson (1979b) Evidence against 
the presence of circulating immune complexes in chronic inflammatory bowel 
disease. GastroenteroZogy ?6, 1380-1385 
Spector, W.G. (1969) The granulomatous inflammatory exudate. Int. Rev. 
Exp. PathoZ. 8, 1-55 
Spector, W.G. & N. Heesom (1969) The production of granulomata by antigen-
antibody complexes. J. PathoZ. 98, 31-39 
Ward, M. (1977) The pathogenesis of Crohn's disease. Lancet 2, 903-905 
Wensinck, F. (1975) The faecal flora of patients with Crohn's disease. 
Antonie van Leeuwenhoek 41, 214-215 
Wensinck, F. (1976) Faecal flora of Crohn's patients. Serological dif-
ferentiation between Crohn's disease and ulcerative colitis. In: The 
management of Grahn's disease. Excerpta Medica, Amsterdam, pp. 103-105 
73 
SUMMARY 
The faecal flora of patients with Grahn's disease has been found to dif-
fer from that of healthy subjects in that the numbers of anaerobic gram-
negative rods and of gram-positive coccoid anaerobes, belonging to 
species of EUbacterium and Peptostreptococ:aus were higher. The flora com-
position was independent of duration of illness and was not influenced 
by ileocaecal resection. Serum agglutinins against some strains of coc-
coid rods were found in a considerable percentage of patients with Grahn's 
disease, whereas percentages of positive sera were much lower in healthy 
subjects and in patients with various diseases. The interpretation of 
these data established by Wensinck and the use of the agglutination re-
actions as a diagnostic test are the subject of this thesis. 
In Chapter 2 recent microbiological and immunological findings in pat-
ients with Grahn's disease are reviewed. They show that in Grahn's dis-
ease as well as in other intestinal diseases, like ulcerative colitis, 
antibodies to dietary and microbial antigens are found frequently. 
In Chapter 3 results are presented of investigations on the prevalence 
of agglutinins to four strains of anaerobic coccoid rods in patients 
with Crohn 1 S disease, ulcerative colitis, a number of other diseases 
and in healthy subjects. Antibodies to coccoid rods were found much more 
frequently in Crdhn's disease than in ulcerative colitis and other dis-
eases. Using the interpretation of agglutination reactions as described 
in Chapter 7, the percentage of false positive results of sera submit-
ted for diagnosis was found to be satisfactorily low. 
The data in Chapter 4 show that the presence of antibodies to the coc-
coid rods in patients with Grahn's disease is correlated with colonic 
disease, the presence of fistulae and with serum immunoglobulin levels. 
No correlation was found between antibodies and any index of disease ac-
tivity. 
In Chapter 5 it is demonstrated that the agglutinins were predominantly 
IgG and less frequently IgM antibodies. Complement fixation only occur-
red with antibodies directed against strain C 18. Strains C 18, Me 46 
and Me 47 activated complement by the alternative pathway. Antibodies 
to the strains Me 44, C 18 and Me 47 were opsonins, in contrast to those 
against strain Me 46. These results suggest that the presence of strain 
Me 46 in the resident intestinal flora is more relevant than that of the 
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other strains. Both properties of strain Me 46, activation of complement 
and resistance to phagocytosis, may be of pathogenetic importance in 
Crohn's disease. The absence of complement fixing and opsonic properties 
of antibodies to strain Me 46 suggest that they belong to the lgG4 sub-
class and possibly are an expression of the genetic predisposition to 
Crohn's disease. 
Logical interpretation of laboratory test results is introduced in Chap-
ter 6 and it is explained why logistic discriminant analysis was applied 
to the interpretation of the agglutination reactions (Chapter 7). By 
application of this technique, 50% of patients with Crohn's disease were 
classified as "probable" or "definite Crohn's diseaseu compared to none 
of the control subjects. It is concluded, therefore, that the agglutina-
tion reactions can be used as a diagnostic test for Crohn's disease. 
Chapter 8 is a general discussion on the relevance of the findings for 
the understanding of the aetiology of Crohn's disease. 
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SANENVATTING 
Door Wensinck werd gevonden dat de fecale flora van patienten met de 
ziekte van Crohn van het ileum verschilde van die van gezonden. Het aan-
tal anaerobe gram-negatieve bacterien was hager en ongeveer 10% van de 
-darmflora bestond uit anaerobe, gram-positieve coccoi"de staafjes beho-
rende tot soorten van de geslachten Eubacterium en Peptostreptococcus, 
die bij gezonden niet of slechts in lage percentages voorkwamen. In een 
haag percentage van sera van patienten met de ziekte van Crohn kwamen 
aggl utini nen voor tegen Stammen van de caeca·; de staafjes, in tegenste 1-
ling tot de sera van gezonden en pati€nten met andere ziekten. 
Het doel van het in dit proefschrift beschreven onderzoek was, inzicht 
te verkrijgen in de betekenis van deze waarnemingen en een methode te 
ontwi kkel en waarmee de aggl uti nati e-reakti es met 4 van de caeca·; de stam-
men als diagnostische test konden worden gebruikt. 
In Hoofdstuk 2 wordt een overzicht gegeven van recente literatuur over 
microbiologische en immunologische bevindingen bij de ziekte van Crohn, 
met name het voorkomen van antistoffen tegen virussen, bacteri€n en 
weefselbestanddelen. Hieruit kon worden geconcludeerd dat zowel bij de 
ziekte van Crohn als bij andere darmziekten, met name colitis ulcerosa, 
hogere percentages antistoffen voorkomen tegen voedings- en microbi€le 
antigenen uit de darm dan bij gezonden. 
In Hoofdstuk 3 worden de resultaten beschreven van het onderzoek naar 
het voorkomen van de anti stoffen tegen de 4 anaerobe cocco"i de staafjes 
bij pati€nten met de ziekte van Crohn, colitis ulcerosa, andere ziekten 
en gezonde controle-personen. Hieruit bleek dat de antistoffen tegen de 
coG:co"ide staafjes bij de ziekte van Crohn veel vaker voorkwamen dan bij 
co1itis ulcerosa en andere ziekten. Sij toepassing van de in Hoofdstuk 
7 beschreven interpretatie van de agglutinatie-reakties, was het per-
centage vals-positieve resultaten bij de voor diagnostische doeleinden 
onderzochte sera bevredigend laag. 
Uit Hoofdstuk 4 blijkt dat het voorkomen van de antistoffen tegen de 
cocco1de staafjes bij de ziekte van Crohn samenhangt met een dikkedarm-
lokalisatie van het ziekteproces, de aanwezigheid van fistels en de 
imrnuunglobuline-spiegels in het serum. Een verband met enige parameter 
voor de ernst van de ziekte bestond niet. 
In Hoofdstuk 5 wordt aangetoond dat de agglutininen voornamelijk lgG en 
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soms lgM antistoffen zijn. Met uitzondering van de antistoffen tegen 
stam C 18 bleken ze geen complement-bindende effectorfunctie te bezit-
ten. De stammen C 18, Me 46 en Me 47 bleken echter zelf complement te 
aktiveren via de alternatieve weg. De antistoffen tegen de stammen Me 
44, C 18 en Me 47 hadden opsoniserende eigenschappen, in tegenstelling 
tot die tegen stam Me 46. Deze waarnemingen doen vermoeden dat de aan-
wezigheid van stam Me 46 in de residente darmflora van patienten met de 
ziekte van Crohn een grotere betekenis heeft dan die van de andere stam-
men. De combinatie van eigenschappen, complement te aktiveren en resi-
stent te zijn tegen fagocytose, kan van pathogenetische betekenis zijn 
voor de ziekte van Crohn. Het ontbreken van complement-bindende en op-
soniserende eigenschappen van de antistoffen tegen Me 46 maakt aanneme-
lijk dat ze tot de lgG4 subklasse behoren en mogelijk een expressie zijn 
van de genetische predispositie voor de ziekte van Crohn. 
In Hoofdstuk 6 wordt een inleiding gegeven tot een logische interpreta-
tie van laboratorium-gegevens en duidelijk gemaakt waarom in Hoofdstuk 
7 logistische discriminant analyse wordt toegepast voor de interpreta-
tie van de agglutinatie-reakties. Met behulp van deze techniek bleek 
het mogelijk,SO% van de patienten met de ziekte van Crohn te classifi-
ceren als "zekere" of "waarschijnlijke ziekte van Crohn"; bij gezonden 
was dit percentage 0. Uit deze gegevens wordt geconcludeerd dat de agglu-
tinatie-reakties bruikbaar zijn als diagnostische test voor de ziekte 
van Crohn. 
Hoofdstuk 8 is een algemene discussie over de gegevens, waarbij wordt 
ingegaan op de mogelijke plaats van deze waarnemingen voor het begrip 
van de etiologie van de ziekte van Crohn. 
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APPENDIX I 
Data are given in the following tables: 
1. patients with Crohn's disease 
2. patients with ulcerative colitis 
3. abnormal findings in Crohn 1 s disease and ulcerative colitis 
Nosographic characteristics in Grahn's disease corre~ated with: 
4. disease restricted to the ileum 
5. disease restricted to the colon 
6. female sex 
7. age 
8. bowel resection 
9. duration of Crohn 1 s disease 
10. abdominal pain 
11. diarrhoea 
12. weight loss 
13. fistulae 
14. bloody stools 
15. fever 
16. Crohn's disease activity index 
17. arthritis or erythema nodosum 
18. a1 -acid glycoprotein 
19. serum albumin 
20. haematocrit 
21. serum IgA 
22. serum IgM 
23. serum IgG 
24. treatment with corticosteroids 
25. treatment with salicylazosulfapyridine 
Nosographic characteristics: 
26. mutually correlated in patients with ulcerative colitis 
27. different frequencies in Crohn's disease and healthy subjects 
28". different frequencies in ulcerative colitis and healthy subjects 
29. different frequencies in ulcerative colitis and Crohn's disease 
of the colon 
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Explanation of abbreviations in Tables 1 and 2 
number: code for the individual patient 
age in years at date of entry in the study 
m/f male or female 
yrs duration of disease at date of entry in the study 
Loo. location of disease at date of entry in the study: 
i = ileum; ic = ileum and colon; c = colon; r = rectum 
CDAI Crohn's disease activity index 
a 1-AGP: a1 -acid glycoprotein level in serum (g/1) 
IgA immunoglobulin A level in serum (mg/100 ml) 
IgM immunoglobulin M level in serum (mg/100 ml) 
IgG immunoglobulin G level in serum (mg/100 ml) 
AggZ. 
aLb. 
results of agglutination reactions with strains Me 44, C 18, Me 
46 and Me 47, respectively, according to strength (0, 1, 2 or 3) 
serum albumin level (g/1) 
symptoms/signs at the date of entry in the study: 
b " bloody stools 
d diarrhoea 
p abdominal pain 
w " weight loss 
ht" low haematocrit 
a " arthritis 
en= erythema nodosum 
PY" pyoderma gangraenosum 
fe" fever 
fi" fistula 
an= anal lesion 
st" stenosis 
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Table 1. Data of patients with Crohn's disease 
Code no.~ m/f l':§. loc. COAl a,-Agp~ IgM .1.9:§_ ~- alb. symptoms/signs 
1002 22 f 5 ic 323 1.9 524 417 1994 3330 42 d,p,w,ht,fe 
1003 29 f 5 ic 164 1.7 268 194 1939 3333 46 ht,fi,st 
1004 48 m 3 c 106 0.8 403 160 1431 3002 41 b,d,ht 
1005 51 m >9 ic 44 1.0 224 100 627 0000 31 d 
1006 56 f >9 c 55 0.7 536 42 1939 0132 50 p, fi 
1007 29 f 4 ic 228 1.7 278 107 1946 2001 39 b,d,ht,fi,st 
1008 38 f 8 i 270 2.1 549 417 1884 3333 44 d,p,w,ht,a,en,fe 
1009 26 m 5 ic 329 1.6 243 121 1564 0301 45 b,p,ht,fi ,st 
1010 25 f 1 ic 293 3.8 561 190 2253 3130 39 p,w,ht,a 
1011 66 m 3 i 248 2.0 442 31 1236 0000 41 b,ht 
1012 25 f >9 175 1.6 433 194 1844 0000 39 d,w,ht,st 
1013 21 f 1 c 447 3.6 114 72 580 0020 35 d,p,w,ht,en,fe,fi 
1014 28 f 1 i 154 0.9 425 385 1047 3301 51 d,p,w,fi 
1015 27 m 6 ic 14 1.2 305 137 1304 3102 55 d 
1016 33 m >9 ic 12 0.6 295 185 1228 2130 49 
1017 44 f 1 i 112 1.1 269 54 1658 0301 41 d 
1018 17 f 3 193 1.5 209 57 982 0210 41 d,p 
1019 21 f <1 c 423 1.7 155 122 1318 3203 45 b,d,p,w 
1020 22 m <1 i 205 1.6 216 122 1228 0031 62 d,p 
1021 54 m >9 c 205 0.8 181 322 1595 3330 49 d 
1022 43 f 5 20 0.8 404 285 2159 1322 42 a 
1023 35 m 1 c 238 1.6 151 107 719 0000 35 b,d 
1024 32 m 4 i 351 1.2 403 244 943 1030 28 d,p,ht,fe,st 
1025 25 m >9 i 66 0.6 118 139 1123 3100 39 p,fi ,st 
1026 33 f 5 c 534 2.3 322 385 784 1000 27 b,d,p,w 
1027 43 f >9 i 78 1.2 520 82 1085 3010 47 d 
1028 23 f 2 i 55 1.0 263 216 1165 0100 49 b,d,p 
1029 41 f 7 i 32 0.9 280 160 1165 0032 48 d 
1030 29 m 4 i 348 2.3 717 119 1749 3330 29 d, p,w,ht, fi,st 
1031 21 f 1 217 2.5 241 220 1019 0010 40 d 
1032 26 f 1 c 188 1.2 238 87 1513 2230 36 d,w,ht,a,en,py 
1033 39 m 7 i 30 1.3 238 60 1085 2200 49 an 
1034 20 m 3 c 54 1.2 362 206 1424 3300 44 d 
1035 52 m 5 j 105 1.3 238 106 1513 3030 49 d,ht 
1036 35 f 8 ic 241 1.8 194 137 904 0030 29 d,p,w,ht 
1037 32 m 1 44 1.2 235 164 1088 0000 54 d 
1038 26 f 2 69 0.7 211 307 1088 2002 53 b 
1039 49 m 7 ic 126 1.0 269 425 1700 3332 43 d,w,ht,fi 
1040 47 f >9 i 121 1.5 81 218 1378 0000 47 p 
1041 19 f 1 c 210 1.7 252 369 1129 3331 42 p,w,a,en,st 
1042 18 m 1 54 0.9 393 157 1353 0030 42 ht 
1043 17 f 4 c 54 0.8 362 297 1217 1310 43 d 
1044 42 f >9 ic 26 0.8 195 231 1305 3303 49 d 
1045 28 f >9 c 31 0.7 491 198 1761 3330 46 
1046 25 m >9 ic 17 0.8 322 284 1337 3332 53 
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Table 1. Data of patients with Crohn's disease(cont'd) 
Code no.~ m/f yrs. lac. CDAI cn-Agp lgA IgM ..!i§_ Aggl. alb. symetoms/signs 
1047 45 m 2 c 95 0.9 287 134 2887 3202 44 d,a 
1048 35 f >9 ic 39 1.3 226 134 1047 1000 49 d 
1049 19 f 3 c 368 1.8 252 366 1608 1300 36 b~d,p ,w,en,py ,fe 
1050 36 m >9 i 34 1.2 186 39 1378 0310 48 d,st 
1051 33 f 7 c 242 1.3 339 212 1490 3133 52 d,p,w~fi 
1052 20 m 6 c 218 0.8 342 121 1327 3330 49 dJi ,st 
1053 46 f 4 i 93 0.7 373 121 958 3300 47 d,p 
1054 27 f 7 c 287 2.6 307 509 1282 3332 32 d,w~ht,a,fi 
1055 38 m 1 ic 204 1.7 415 54 996 0000 33 d,p ,w,ht 
1056 19 f 1 c 396 2.4 342 220 1458 0300 36 b,d,p,w~ht,en 
1057 42 m >9 ic 42 1.3 191 54 883 3133 35 
1058 51 f 1 c 372 2.4 342 211 1505 3332 27 b,d,w,ht,a,en,fi 
1059 61 m 1 154 1.9 448 54 845 0000 27 d,w 
1060 22 m 6 ic 240 1.5 223 73 1156 0000 36 d 
1061 41 f 3 12 1.0 299 93 1842 3330 46 d 
1062 39 f 5 138 0.6 142 246 1569 2000 50 b,d,p 
1063 53 f 4 i 162 1.7 186 75 1460 2200 45 d,w 
1064 37 f 6 i 14 1.6 226 155 1077 0000 42 
1065 42 f 5 38 1.4 226 375 1033 2332 48 fi 
1066 45 m 1 i 188 1.4 234 125 1250 0003 50 d,p,w,st 
1067 60 m 5 c 204 1.7 229 103 904 3333 43 d,fi,st 
1068 25 f 3 c 160 1.0 218 190 1623 0030 42 b,d,p 
1069 24 f 2 c 212 1.6 409 131 1077 3230 42 d,p~w,st 
1071 33 m 1 i 276 1.2 203 40 1033 2010 38 b,d,p,w,fi 
1072 26 f 8 i 213 1.2 182 163 1077 3102 32 p,ht,a,fi 
1073 22 m 1 i 94 1.0 373 93 1475 0302 47 d 
1074 29 f 5 c 30 0.9 356 200 1844 2000 58 
1075 28 f 6 c 145 0.8 234 206 1614 3010 39 b,d,st 
1076 71 f 5 c 226 2.0 234 300 1382 2301 33 b,d,ht 
1077 30 f >9 i 75 1.5 167 263 1029 3123 43 d,p 
1078 30 f >9 i 30 0.6 43 200 693 0000 48 p,fi 
1082 29 f >9 ic 340 4.1 235 218 897 1232 30 d,p,ht,fe,fi 
1083 25 f 1 224 1.9 233 255 1216 0102 45 d,p,st 
1084 34 m <1 c 476 5.1 314 255 1864 3120 28 b,d,p,w,ht,fe,fi 
1085 21 f >9 ic 110 1.1 280 200 1216 1332 40 d,p,w, fi 
1087 55 f >9 ic 119 0.6 495 255 1419 2002 43 d,p 
1088 38 m 1 i 146 1.1 187 135 620 0002 35 d,p,w,st 
1089 27 f 3 c 415 2.2 253 220 1027 3330 28 d,p,w,ht,fe.fi 
1090 29 f <1 ic 288 4.4 257 425 1221 1302 39 b,d,p,w,fe,fi,an 
1091 33 f >9 c 125 1.3 229 229 1430 0000 42 b,d,p 
1092 25 f 1 c 10 1.0 214 124 1308 0000 49 
1093 32 m >9 i 10 1.5 490 282 1522 0200 45 
1094 32 f 7 i 48 0.8 164 193 947 3300 40 d,fi 
1095 14 m 2 c 265 3.2 690 139 947 0330 30 d,p,w,ht,fi 
1096 20 f 2 c 80 0.8 188 131 1108 2230 46 d,w 
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Table 1. Data of patients with Crohn's disease (eont'd) 
Code no. age m/f yrs. loc. COAl Ct,-Agp ~ IgM .l1§_ Aggl. alb. symptoms/signs 
1097 55 f 8 97 0.8 386 247 1065 2132 42 d,p,fi,st 
1098 40 f 6 i 105 1.0 83 104 632 3001 54 d,p 
1099 34 f <1 c 129 1.2 231 193 1740 3330 37 d,w 
1100 27 f 5 c 327 3.7 161 237 875 3130 27 b,d,ht,a,en,py,fe 
1101 62 f >9 c 60 1.1 303 66 1221 0000 48 d,a 
1104 40 f 3 i 38 0.6 191 202 1430 3000 48 d,ht 
1105 45 m 8 c 30 0.8 196 103 1470 1331 52 
1107 18 m 1 c 242 1.5 312 185 1462 1330 52 d,p,w,ht 
1108 44 f >9 ic 127 1.1 247 376 1740 1300 40 d ,p 'fi 
1109 32 f 7 c 42 0.7 199 724 1619 3323 40 d 
1110 38 f >9 i 50 0.7 332 283 999 0000 52 p 
1111 74 f 1 c 203 1.8 83 724 1186 3030 35 b,d,p,w,ht,fi 
1112 25 f 5 ic 84 0.9 329 168 1366 0030 50 p 'fi 
1113 68 m 1 c 70 0.7 724 100 1423 3000 46 b,d,w 
1114 18 f 3 ic 10 0.6 214 276 1683 3000 42 
1117 22 m 4 c 27 0.8 194 211 913 0000 52 
1118 25 f 1 c 282 1.8 180 131 1164 0000 30 b,d,p,w 
1119 28 m 2 ic 106 2.0 390 346 2133 3332 46 d,ht,an 
1120 50 f 2 c 241 1.7 194 26 626 0000 28 b,d,p,w,ht 
1121 18 m 4 c 0 1.7 338 246 1491 0000 52 
1122 44 f 4 i 150 0.5 192 229 1303 0000 44 d,p,w,st 
1123 61 m <1 c 35 1.2 366 227 1005 2030 50 b,p 
1124 18 f <1 c 70 0.6 137 267 2206 0230 40 b,d,p 
1125 26 f <1 ic 240 2.5 199 210 1552 0000 38 b,d,p,w 
1126 22 f 5 ic 50 0.6 338 103 1533 2020 42 
1127 29 m 5 c 30 1.0 563 220 1398 3120 49 d 
1128 30 f 2 c 166 1.8 37 235 932 3300 29 b,d,p,w,ht,fe 
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Table 2. Data of patients with ulcerative colitis 
Code no. age m/f yrs. 1 oc. COAl ~ IgA lgM ~ Aggl. alb. symptoms/signs 
2001 27 m 3 c 100 0.9 197 87 984 0000 52 b 
2004 47 m 2 c 18 0.9 252 112 1345 0000 49 b 
2005 25 m 7 c 84 1.1 474 125 2151 1330 47 ht 
2006 67 m 5 c 134 1.0 147 99 910 0000 57 d 
2007 63 f 2 c 345 1.7 578 93 1345 0000 44 b,d,w,ht 
2008 53 m 3 r 203 1.6 103 208 910 0000 52 d 
2009 37 f 2 r 240 1.4 295 335 1345 0100 43 b,d 
2010 28 f 3 c 0 0.8 147 268 1098 0100 52 d 
2011 48 m >9 c 100 0.9 282 161 1252 0000 51 b,d 
2013 18 m 2 c 0 0.8 22 238 1950 0000 57 d 
2014 64 m <1 c 352 1.6 366 182 1971 0000 30 b,d,w,ht,fe,fi 
2015 29 m >9 c 18 0.8 155 186 2003 0000 54 b 
2016 36 f 3 c 120 0.9 285 174 1335 0000 51 b,d,a 
2017 26 f 1 c 219 2.4 262 61 1123 0010 28 b,ht 
2018 34 f 4 c 130 0.7 162 211 1047 0000 46 d 
2019 63 m 5 c 70 1.1 257 154 2055 0000 44 b,d 
2020 32 f >9 c 56 1.0 440 220 1426 2020 41 
2021 38 f >9 c 210 1.4 342 214 2323 0100 45 b,d 
2022 29 m 8 c 12 0.7 218 356 1047 3000 54 
2023 28 f 6 c 130 0.7 230 130 1058 0030 49 d 
2024 56 m 2 c 161 1.0 289 144 1565 0000 49 b,d,w,ht 
2025 35 f 3 c 79 0.5 214 40 984 0000 56 
2026 68 m >9 c 30 0.2 246 123 1752 3300 51 d 
2027 33 m 1 c 345 1.7 298 151 1201 0000 43 b,d,ht 
2028 35 f >9 c 165 0.7 170 130 1345 2000 43 d,p 
2029 83 m 1 r 24 1.0 324 151 1474 0000 49 
2030 27 f 1 r 56 0.6 315 90 873 0000 45 d 
2031 18 f >9 c 6 0.9 192 174 1021 0000 52 
2032 24 f 4 r 120 1.2 230 197 984 0000 47 b,p 
2033 47 m 2 r 54 1.0 124 90 1165 0000 43 d,ht 
2034 25 f 1 c 0 0.8 112 194 1603 0000 51 b,d 
2035 25 m 3 c 124 0.6 238 147 1501 0100 50 b,d 
2036 32 f 6 c 0 0.5 238 170 2212 0000 52 
2037 23 f 4 r 175 1.0 83 124 1031 0000 51 b,p 
2038 64 m 6 c 56 1.1 294 90 2323 3310 45 ht 
2040 45 f 7 r 0 0.6 185 117 902 0200 51 
2041 29 m 3 c 91 1.1 138 159 1335 0000 46 b 
2042 20 f 4 c 42 0.8 94 457 1164 0010 49 
2043 24 m 7 r 60 0.6 72 178 1164 0000 57 
2045 18 f 6 r 148 0.8 315 178 1759 0000 49 b,d 
2046 27 f 8 c 0 0.9 481 209 1738 3233 44 
2047 30 f 6 c 338 2.6 133 68 1016 0000 35 b,d,p,w 
2048 53 m 8 c 18 0.5 157 144 1236 0000 48 
2049 28 m 2 r 30 1.0 147 103 766 0000 49 b,d 
2050 35 m >9 r 132 0.7 320 175 1194 1000 48 b,d,p,ht,a,en 
2051 54 f 3 c 10 0.7 283 140 1191 0001 48 
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TabZe 3. Nosographie eharaeteristies in patients with Crohn's disease 
and uZeerative eoZitis 
abdominal pain 
bloody stools 
diarrhoea 
weight loss 
fever 
fistulae 
arthritis/erythema 
nodosum 
bowel resection 
COAl > 150 
a 1-acid glycoprotein 
>1.1 g/1 
low haematocrit 1 
albumin < 35 g/1 
IgA < 72 mg/100 ml 2 
IgA > 455 mg/100 ml 
IgM < 52 mg/100 ml 
lgM > 355 mg/100 ml 
lgG < 600 mg/100 ml 
IgG > 1767 mg/100 ml 
PREVALENCE OF ABNORMAL FINDINGS (%) 
Crohn 1 s disease 
of 
~ ileocolon ~ 
(n=46) (n=26) (n=47) 
50 
11 
75 
23 
5 
20 
2 
50 
34 
55 
20 
9 
2 
9 
7 
7 
0 
9 
46 
15 
65 
31 
12 
31 
8 
65 
42 
58 
38 
15 
0 
12 
0 
15 
0 
19 
45 
43 
81 
47 
13 
23 
19 
32 
55 
60 
32 
23 
2 
11 
4 
13 
2 
11 
Ulcerative colitis 
(n=46) 
11 
48 
52 
9 
2 
2 
4 
24 
24 
20 
20 
4 
2 
7 
2 
4 
0 
17 
1 ) men: <0.47; women: <0.42. 
2 ) Cutoff values of immunoglobulin levels represent 2.5 (lower limits) 
and 97.5 (upper limits) percentiles of values in healthy subjects. 
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Table 4. Nosographic characteristics correlated 
with Grahn's disease restricted to ileum 
CORRELATION WITH ILEAL DISEASE x 
positive: 
negative: 
x: p < 0.05 
serum albumin 
bloody stools 
IgG 
agglutination of Me 44 
posterior probability 
Table 5. Nosographic characteristics correlated 
with Grahn's disease restricted to colon 
CORRELATION WITH COLONIC DISEASE x 
positive: weight loss 
·bloody stools 
arthritis/erythema nodosum 
CDAI 
negative: ·duration of disease 
bowel resection 
x: p < 0.05; • : p < 0.01 
Table 6. Nosographic characteristics correlated 
with female sex of patients with Crohn's disease 
CORRELATION WITH FEMALE SEXx 
positive: abdominal pain 
arthritis/erythema nodosum 
·lgM 
X: p < 0.05; •: p < 0.01 
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Tab~e 7. Nosographic characteristics eorretated 
with age of patients with Crohn's disease 
CORRELATION WITH AGEx 
positive: duration of disease 
negative: COAl 
·lgM 
X: p < 0.05 
Tabl.e 8. Nosographic characteristics correlated 
with bowel, resection of patients with Grahn's 
disease 
CORRELATION WITH BOWEL RESECTIONx 
positive: ~duration Of disease 
·serum albumin 
•haematocrit 
negative: abdominal pain 
•wei ght loss 
bloody stools 
·COAl 
•a1-acid glycoprotein 
disease restricted to colon 
·treatment with corticosteroids 
treatment with SASP 
x: p <.0.05; •: p < 0.01 
Table 9. Nosographic characteristics correlated 
with duration of Crohn's disease 
CORRELATION WITH DURATION OF DISEASEx 
positive: age 
·bowel resection 
negative: ·weight loss 
·bloody stools 
·COAl 
·a1-aci d glycoprotein 
·disease restricted to colon 
X: P< 0.05; ·: P< 0.01 
Table 10. Nosographic characteristics correlated 
with abdominal pain in patients with Crohn's disease 
CORRELATION WITH ABDOI41NAL PAIN x 
positive: female sex 
·weight loss 
·fever 
bloody stools 
·fistulae 
·COAl 
a 1-acid glycoprotein 
negative: bowel resection 
serum albumin 
!gG 
X: p < 0.05; .:P < 0.01 
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Table 11. Nosog~aphi~ characteristics correlated 
with diarrhoea in patients with Grahn's disease 
CORRELATION WITH OIARRHOEAx 
positive: ·weight loss 
·COAl 
a,-acid glycoprotein 
negative: ·serum albumin 
x: p < 0.05; • p < 0.01 
Table 12. Nosographic characteristics correlated 
with weight loss in patients with Crohn's disease 
CORRELATION WITH WEIGHT LOSSx 
positive: ·abdominal pain 
·diarrhoea 
·fever 
arth ri t i s/er.ythema nodosum 
disease restricted to colon 
·COAl 
·a1-acid glycoprotein 
·treatment with corticosteroids 
negative: ·duration of disease 
·bowel resection 
·serum albumin 
• haematocri t 
x: p < 0.05;· p < 0.01 
Table 13. Nosographic characteristics correlated 
with fistulae in patients with Grahn's disease 
CORRELATION WITH FISTULAEx 
positive: ·abdominal pain 
·COAl 
·agglutination of c 18 
agglutination of Me 46 
agglutination of Me 47 
•posterior probability 
negative: serum albumin 
haematocrit 
x: p < 0.05; •: p < 0.01 
Table 14. Nosographic characteristics correlated 
with bloody stools in patients with Crohn's disease 
CORRELATION WITH BLOODY STOOLSx 
positive: abdominal pain 
·COAl 
a1 -acid glycoprotein 
·disease restricted to colon 
negative: ·duration of disease 
bowel resection 
disease restricted to ileum 
·serum albumin 
agglutination of Me 46 
posterior probability 
x: p < 0.05; ·: p < 0.01 
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Table 15. Nosographic eh~aeteristies co~eZated 
with fever in patients with Crohn's disease 
CORRELATION WITH FEVER x 
positive: ·abdominal pain 
·weight 1 oss 
bowel resection 
arthritis/erythema nodosum 
·CDAI 
·a1 -acid glycoprotein 
·lgM 
posterior probability 
negative: ·serum albumin 
·haematocrit 
x: p < 0.05; •: p < 0.01 
Table 16. Nosographic characteristics corretated 
with the Crohn 's disease ac:tivity index (CDAI) in 
patients with Grahn's disease 
CORRELATION WITH CDA!x 
positive: •bloody stools 
disease restricted to colon 
•a1 -acid glycoprotein 
·treatment with corticosteroids 
negative: age 
•duration of disease 
•bowel resection 
·serum albumin 
x: p < 0.05; ·: p < 0.01 
Tabte 1?. Nosographic characteristics corretated 
with a::t>thritis/erythema nodoswn in patients with 
Grahn's disease 
CORRELATION WITH ARTHRITIS/ERYTHEMA NODOSUMx 
positive: weight loss 
fever 
negative: 
·COAl 
·a1 -acid glycoprotein 
agglutination of C 18 
female sex 
disease restricted to colon 
serum albumin 
·haematocrit 
x: p < 0.05; •: p < 0.01 
Table 18. Nosographic characteristics corretated 
with a 1-aeid gZycoprotein in patients with Grahn's 
disease 
CORRELATION WITH a1 -AC!O GLYCOPROTE!Nx 
positive: abdominal pain 
•weight loss 
diarrhoea 
·fever 
bloody stools 
·arthritis/erythema nodosum 
·COAl 
·treatment with corticosteroids 
negative: ·duration of disease 
·bowel resection 
·serum albumin 
·haematocrit 
x: p < 0.05; •: p < 0.01 
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TabZe 19. Nosographic characteristics correlated 
with serum albumin in patients with Grahn's 
disease 
CORRELATION WITH SERUM ALBUMIN x 
positive: •bowel resection 
negative: 
disease restricted to ileum 
·haematocrit 
abdominal pain 
•weight loss 
·diarrhoea 
·fever 
·bloody stools 
fistulae 
arthritis/erythema nodosum 
•COAl 
•a1-acid.glycoprotein 
treatment with corticosteroids 
x: p < 0.05; ·: p < 0.01 
TabZe 20. Nosographic characteristics correlated 
with haematocrit vaZue in patients with Crohn 's 
disease 
CORRELATION WITH HAE~1ATOCR!Tx 
positive: ·serum albumin 
·bowel resection 
negative: •weight loss 
·fever 
fistulae 
·arthritis/erythema nodosum 
·COAl 
·a1 -acid glycoprotein 
agglutination of Me 46 
posterior probability 
x: p < 0.05; ·: p < 0.01 
Table 21. Nosographic characteristics correlated 
with serum IgA in patients with Crohn's disease 
CORRELATION WITH IGA x 
positive: posterior probability 
x: p < 0.05 
Table 22. Nosographic characteristics correlated 
with serum IgM in patients with Crohn's disease 
CORRELATION WITH IGM x 
positive: ·fever 
·female sex 
IgG 
•agglutination of Me 44 
agglutination of C 18 
posterior probability 
negative: ·age 
x: p < 0.05; •: p < 0.01 
Table 23. Nosographic characteristics correlated 
with serum IgG in patients with Crohn's disease 
CORRELATION WITH IGG x 
positive: IgM 
rzegative: 
agglutination of Me 44 
·agglutination of c 18 
·posterior probability 
abdominal pain 
disease restricted to ileum 
x: p < 0.05; ·: p < 0.01 
93 
94 
Tab%e 24. Nosographic characteristics correlated 
with treatment with corticosteroids of patients 
with Crohn's disease 
CORRELATION WITH CORTICOSTERO!DSx 
positive: •weight loss 
·COAl 
negative: 
·a1-acid glycoprotein 
serum albumin 
·bowel resection 
x: p < 0.05; •: p < 0.01 
Table 25. Nosographic characteristics eorTelated 
with treatment with saZicyZazosuZfapyridine (SASP) 
of patients ~th Grahn's disease 
CORRELATION WITH SASPx 
negative: bowe 1 resection 
x: p < 0.05 
Table 26. Nosographic characteristics mutually correlated 
in patients with ulcerative colitis 
CHARACTERISTICS MUTUALLY CORRELATEOx 
weight loss and low haematocrit 
weight loss and short duration of disease 
·weight loss and COAl 
weight loss and bloody stools 
COAl and low haematocrit 
COAl and bloody stools 
-COAl and low serum albumin 
-COAl and a,-acid glycoprotein 
a,-acid glycoprotein and low haematocrit 
a,-acid glycoprotein and low serum albumin 
serum albumin and haematocrit 
lgA and low haematocrit 
duration of disease and posterior probability 
!gA and lgG 
lgA and age 
·duration of disease and agglutination of Me 44 
bloody stools and no agglutination of Me 44 
bloody stools and low posterior probability 
x: p < 0.05; . : p < 0.0025 
Table 27. Nosographic character-istics with higher frequency in 
patients with Crohn's disease than in healthy subjects 
CHARACTERISTICS WITH HIGHER FREQUENCY IN CROHN'S DISEASE 
·a,-acid glycoprotein 
·lgG (higher level) 
·agglutination of Me 44 
·agglutination of C 18 
•agglutination of Me 46 
·agglutination of Me 47 
·posterior probability (higher value) 
• : p < 0.0001 
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Table 28. Nosographic characteristics with higher frequency in 
patients with ulcerative colitis than in healthy subjects 
CHARACTERISTICS WITH HIGHER FREQUENCY IN ULCERATIVE COLIT!Sx 
·a,-acid glycoprotein (higher level) 
!gG (higher level) 
agglutination of C 18 
·agglutination of Ne 46 
·posterior probability (higher value) 
x: p < 0.05; ·: p < 0.01 
Table 29. Nosographic characteristics with higher frequency in 
patients with Crohn's disease of the colon than in patients with 
ulcerative colitis 
CHARACTERISTICS WITH HIGHER FREQUENCY IN COLONIC CROHN'S DISEASEx 
·diarrhoea 
·abdominal pain 
·weight loss 
arthritis/erythema nodosum 
·fistulae 
·CDAI (higher value) 
a1-acid glycoprotein(higher level) 
·lgM (higher level) 
•agglutination of Me 44 
•agglutination of C 18 
·agglutination of Me 46 
·agglutination of Me 47 
•posterior probability (higher value) 
·low serum albumin 
x: p < 0.05; •: p < 0.01 
APPENDIX II 
Logistic discriminant analysis (Anderson, 1972) was used to discrimi-
nate between patients with Crohn's disease (CD) and healthy subjects(HS) 
on the basis of the agglutination reactions. The a posteriori probabil-
ity of CD can be written as: 
1 
(1) 
In this formula, x1-x4 are the results of the agglutination reactions 
with strains ~1e 44, C 18, Me 46 and ~1e 47, respectively. The expression 
is known as the multivariate logistic function. The coefficients s0-s4 
were estimated with the maximum likelihood method (Cox, 1970) and the 
estimates are denoted by b0-b4, respectively. The estimated a posteriori 
probability of CO can thus be written as: 
1 
The estimates b0-b4 are obtained from the reference samples (n1 patients 
with CD and n2 healthy subjects) with a priori probabilities P(CD) and 
P(HS) proportional to the sample sizes n1 and n2: 
n1 
P(CD) = --"--
n1 + n2 
P(HS) n2 
If a posteriori probabilities have to be calculated from other a priori 
probabilities Q(CD) and Q(HS) = 1- Q(CD), b0 is replaced by d0: 
n1 Q(HS) 
d0 = b0 + ln--;;;- + ln Q(CD) 
Results. With the results of the agglutination reactions x1(Me 44), 
x2 (C 18), x3 (Me 46) and x4 (Me 47) of 114 patients with CD and 95 
healthy subjects, the coefficients s0 - s4 in (1) were estimated: 
(3) 
(4) 
(5) 
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b1 = -0.45 
b2 = -0.95 
b3 = -2.32 
b4 = -1.04 
The coefficient b0 is connected with a pPioPi probabilities: 
P(CD) = 114/209 = 0.54; P(HS) = 0.46 
(6) 
For equal a pPioPi probabilities Q(CD) = Q(HS) 0.5, coefficient bo 
is replaced by d0 according to (4), thus: 
do = 1.51 (7) 
The other coefficients remain unchanged. The 95% confidence intervals 
for these coefficients are: 
-o.86 < s1 < -o.o5 
-1.51 < s2 < -0.38 
-4.23 < s3 < -0.41 
-1.77 < s4 < -0.31 (8) 
From (8) it is concluded that coefficients s1 - s4 differ significant-
ly from 0 (a= 0.05). With the estimated coefficients (6) and (7) the 
a postePioPi probabilities were calculated for the agglutination reac-
tions of the patients with Crohn's disease and of healthy subjects 
(Table 1), as well as for all possible agglutination reactions (Table 
2). 
Verification. Up to here, the results of allocation are mentioned for 
the same elements as those with which the coefficients of the logistic 
function were estimated (see Chapter 7). It would be better to evaluate 
the classification_in new samples from the patients with Crohn 1 S dis-
ease and healthy subjects. As these samples were not available, a split-
sample method was used. The sample consisting of 114 patients with 
CO has been randomly divided into two groups of 57 subjects. The sample 
consisting of 95 healthy subjects has been divided in a group of 48 and 
one of 47 subjects. With the agglutination results of the first group 
of 57 patients with CD and the group of 48 healthy subjects, new coef-
ficients were estimated. The results, for equal a priori probabilities 
are: 
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d0 = 1.75 
b1 = -0.56 
b2 = -0.94 
b3 = -2.01 
b4 = -1.66 (9) 
The a posteriori probabilities for the elements of both groups, as 
determined with these coefficients, are summarized in Table 3. From 
this table it is seen that the results of both groups are similar. 
It is concluded, therefore, that the coefficients (6) and (7) obtain-
ed with the original samples may be used (see Chapter 7). 
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TabZe 1. Frequency distribution of agglutination rea~tions in 114 
patients with Crohn's disease (CD) and 95 healthy subjeets (HS) 
AGGLUTINATION* CD HS AGGLUTINATION* CD HS 
0 0 0 0 21 75 2 0 0 0 1 5 
0 0 0 1 0 1 2 0 0 1 1 0 
0 0 0 2 2 1 2 0 0 2 2 0 
0 0 0 3 1 0 2 0 1 0 1 0 
0 0 1 0 1 0 2 0 3 0 1 0 
0 0 2 0 1 0 2 1 3 0 1 0 
0 0 3 0 3 0 2 1 3 2 1 0 
0 0 3 1 1 0 2 2 0 0 3 1 
0 0 3 2 1 0 2 2 3 0 2 0 
0 1 0 0 0 2 2 3 0 1 1 0 
0 1 0 1 0 1 2 3 3 2 1 0 
0 1 0 2 1 0 3 0 0 0 3 2 
0 1 1 0 1 0 3 0 0 1 1 0 
0 1 3 2 1 0 3 0 0 2 1 0 
0 2 0 0 2 0 3 0 1 0 2 1 
0 2 3 0 1 0 3 0 3 0 2 0 
0 3 0 0 1 1 3 1 0 2 2 0 
0 3 0 1 2 0 3 1 2 0 1 0 
0 3 0 2 1 0 3 1 2 3 1 0 
0 3 1 0 1 0 3 1 3 0 2 0 
0 3 3 0 1 0 3 1 3 3 2 0 
1 0 0 0 3 4 3 2 0 2 1 0 
1 0 0 2 0 1 3 2 0 3 1 0 
1 0 2 0 1 0 3 2 3 0 1 0 
1 2 3 2 1 0 3 3 0 0 3 0 
1 3 0 0 2 0 3 3 0 1 1 0 
1 3 0 2 1 0 3 3 0 3 1 0 
1 3 1 0 1 0 3 3 2 3 1 0 
1 3 2 2 1 0 3 3 3 0 9 0 
1 3 3 0 1 0 3 3 3 1 1 0 
1 3 3 1 1 0 3 3 3 2 4 0 
1 3 3 2 1 0 3 3 3 3 3 0 
*) Agglutination reactions with strains Me 44, c 18, Me 46 and Me 47, 
respectively, according to strength. 
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Table 2. A posteriori probabilities P(CDixJ of Grahn's disease at 
a priori probability of 0.5 for all agglutination reactions with 
strains Me 44:> C 18:> Me 46 and Me 46:> respectively 
AGGLUT. P(CD!x) AGGLUT. P(CD!x) AGGLUT. P(CD!x) AGGLUT. P(CD!x) 
0000 0.18 0231 1 1122 1 2013 0.99 
0001 0.38 0232 1 1123 1 2020 0.98 
0002 0.64 0233 1 1130 1 2021 0.99 
0003 0.83 0300 0.79 1131 1 2022 1 
0010 0.69 0301 0.92 1132 1 2023 1 
0011 0.86 0302 0.97 1133 1 2030 1 
0012 0.95 0303 0.99 1200 0.70 2031 1 
0013 0.98 0310 0.97 1201 0.87 2032 1 
0020 0.96 0311 0.99 1202 0.95 2033 1 
0021 0.98 0312 1 1203 0.98 2100 0.58 
0022 0.99 0313 1 1210 0.96 2101 0.80 
0023 1 0320 1 1211 0.99 2102 0.92 
0030 1 0321 1 1212 0.99 2103 0.97 
0031 1 0322 1 1213 1 2110 0.93 
0032 1 0323 1 1220 1 2111 0.98 
0033 1 0330 1 1221 1 2112 0.99 
0100 0.36 0331 1 1222 1 2113 1 
0101 0.62 0332 1 1223 1 2120 0.99 
0102 0.82 0333 1 1230 1 2121 1 
0103 0.93 1000 0.26 1231 1 2122 1 
0110 0.85 1001 0.50 1232 1 2123 1 
0111 0.94 1002 0.73 1233 1 2130 1 
0112 0.98 1003 0.89 1300 0.86 2131 1 
0113 0.99 1010 0.78 1301 0.94 2132 1 
0120 0.98 1011 0.91 1302 0.98 2133 1 
0121 0.99 1012 0.97 1303 0.99 2200 0.78 
0122 1 1013 0.99 1310 0.98 2201 0.91 
0123 1 1020 0.97 1311 0.99 2202 0.97 
0130 1 1021 0.99 1312 1 2203 0.99 
0131 1 1022 1 1313 1 2210 0.97 
0132 1 1023 1 1320 1 2211 0.99 
0133 1 1030 1 1321 1 2212 1 
0200 0.60 1031 1 1322 1 2213 1 
0201 0.81 1032 1 1323 1 2220 1 
0202 0.92 1033 1 1330 1 2221 1 
0203 0.97 1100 0.47 1331 1 2222 1 
0210 0.94 1101 0.72 1332 1 2223 1 
0211 0.98 1102 0.88 1333 1 2230 1 
0212 0.99 1103 0.95 2000 0.35 2231 1 
0213 1 1110 0.90 2001 0.61 2232 1 
0220 0.99 1111 0.96 2002 0.81 2233 1 
0221 1 1112 0.99 2003 0.92 2300 0.90 
0222 1 1113 1 2010 0.85 2301 0.96 
0223 1 1120 0.99 2011 0.94 2302 0.99 
0230 1 1121 1 2012 0.98 2303 1 
cont'd on next page 
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Table 2. eont'd 
AGGLUT. P(CD!xJ AGGLUT. P(CD!x) AGGLUT. P(~Dix) AGGLUT. P(CD!x) 
2310 0.99 3020 0.99 3130 1 3300 0.94 
2311 1 3021 1 3131 1 3301 0.98 
2312 1 3022 1 3132 1 3302 0.99 
2313 1 3023 1 3133 1 3303 1 
2320 1 3030 1 3200 0.85 3310 0.99 
2321 1 3031 1 3201 0.94 3311 1 
2322 1 3032 1 3202 0.98 3312 1 
2323 1 3033 1 3203 0.99 3313 1 
2330 1 3100 0.69 3210 0.98 3320 1 
2331 1 3101 0.86 3211 0.99 3321 1 
2332 1 3102 0.95 3212 1 3322 1 
2333 1 3103 0.98 3213 1 3323 1 
3000 0.46 3110 0.96 3220 1 3330 1 
3001 0.71 3111 0.98 3221 1 3331 1 
3002 0.87 3112 0.99 3222 1 3332 1 
3003 0.95 3113 1 3223 1 3333 1 
3010 0.90 3120 1 3230 1 
3011 0.96 3121 1 3231 1 
3012 0.99 3122 1 3232 1 
3013 0.99 3123 1 3233 1 
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Table 3. Fre[uency distribution of a posteriori probabilities of Cro~'s 
disease P(CD x) for the elements from the first sub-scunple of 57 pa:tients 
with Crohn's disease (CD) and 48 healthy subjects (HS) and the second sub-
scunple of 57 patients with CD and 47 HS, with use of coefficients (9) 
P(CDix) SUB-SAI1PLE 1 SUB-SAMPLE 2 
CD HS CD HS 
0 - <0.10 0 0 0 0 
0.10 - <0.20 9 38 12 37 
0.20 - <0.30 0 3 3 1 
0.30 - <0.40 1 3 0 4 
0.40 - <0.50 1 1 2 2 
0.50 - <0.60 2 0 1 0 
0.60 - <0.70 0 0 0 0 
0.70- <0.80 4 2 3 1 
0.80 - <0.85 4 0 1 1 
0.85 - <0.90 1 1 1 1 
0.90 - <0.95 5 0 5 0 
0.95 - <0.99 6 0 6 0 
0.99 - 1 24 0 23 0 
Total 57 48 57 47 
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DANKWOORD 
Voor het totstandkomen van dit proefschrift was de medewerking van 
velen een noodzakelijke of bijdragende faktor. Ik wil hen allen har-
telijk bedanken en enkelen met name noemen: 
Prof. Dr F. Wensinek, mijn promotor, bood mij de gelegenheid aan het 
onderzoek mede te werken. Behalve door de ontelbare gesprekken met hem 
over het onderzoek-, is zijn stimulerende invloed terug te vinden in de 
wijze waarop de resultaten zijn beschreven: met veel geduld heeft hij 
mij telkens weer duidelijk gemaakt dat een zekere "liefde voor de lezer" 
ook noodzakelijk was. 
De heer R. van Strik, mijn tweede promotor, ben ik erkentelijk voor zijn 
bereidheid de statistische lading van het proefschrift te dekken na mij 
enkele malen met zachte hand een rechter statistisch spoor te hebben 
gewezen. 
Prof. Dr M. Frenkel bood mij reeds tijdens mijn opleiding tot internist 
de gelegenheid onderzoek te verrichten. Als opleider heeft hij een stern-
pel gedrukt op mijn aanpak van medische problemen, als co-referent lever-
de hij waardevolle opmerkingen. 
Paul Wilson dank ik eveneens voor zijn opmerkingen als co-referent; 
bovendien behoedde hij mij voor al te vrije interpretaties van de 
Engelse spraakkunst. 
Gerda Briggeman voerde op zelfstandige en voorbeeldige wijze alle expe-
rimenten uit. 
Jan Dees en Mark van Blankenstein dragen de verantwoordelijkheid voor 
de diagnose van de meeste patienten. Zander hun welwillende medewerking 
bij het verkrijgen van klinische gegevens over en bleed van de patienten, 
was het onderzoek niet mogelijk geweest. 
Dr D.L. Westbroek gaf mij de gelegenheid op elk moment in zijn gegevens 
te snuffelen. Bovendien ben ik hem dankbaar omdat hij in 1972 aan Prof. 
Wensinck vroeg of hij eens naar de darmflora van patienten met de ziekte 
van Crohn wilde kijken. 
Paul Schmitz heeft op prettige wijze ervoor gezorgd dat een groat aantal 
patientengegevens met de computer kon worden geanalyseerd. In de vele 
gesprekken die ik met hem had, zijn mij vele mogelijkheden en onmogelijk-
heden van de toegepaste statistiek duidelijker geworden. 
Gesprekken met Jaap van der Sluis leidden tot een versneld uitkristalli-
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seren van conclusies uit enkele immunologische valstrikken. 
Zander de hulp van de medewerkers van de poliklinieken Inwendige Genees-
kunde II en Heelkunde, met name Jeanine Boender~ EZZeke SchaZekamp en 
Liesbeth Benckhuysen-Bongers zou het onderzoek aanzienlijk moeizamer 
zijn verlopen. 
Tenslotte dank ik PauZa DeZfos voor haar hulp bij het maken van de 
omslagfoto. 
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CURRICULUM VITkE 
De schrijver van dit proefschrift werd in 1945 geboren. In 1963 
behaalde hij het diploma HBS-B aan het Groen van Prinsterer-
lyceum te Vlaardingen. De studie in de geneeskunde vond plaats 
aan de Rijksuniversiteit te Leiden. Na het doctoraalexamen in 
1968 werden de co-assistentschappen gevolgd aan de Medische Facul-
teit te Rotterdam. Het artsexamen werd afgelegd in 1971. Na het 
vervullen van de militaire dienstplicht volgde specialisatie in 
de inwendige geneeskunde op de afdeling Interne Geneeskunde II 
(Hoofd: Prof. Dr M. Frenkel) van het Academisch Ziekenhuis Dijk-
zigt te Rotterdam en werd hij in 1977 in het specialistenregister 
ingeschreven. Sedert 1975 is de schrijver verbonden aan de afde-
ling Medische Microbiologie (Hoofd: Prof. Or F. Wensinck) van de 
Erasmus Universiteit te Rotterdam. 
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